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ABSTRACT 
 
Gouwens, Lisa K. Ph.D., University of Missouri-St. Louis, December 2017. Interactions 
between amyloid-beta and microglial cells. Major Professor: Michael R. Nichols. 
 
Alzheimer’s disease (AD), the most common cause of dementia, is a 
neurodegenerative condition characterized by loss of memory and intellectual abilities. 
Intracellular plaques of aggregated amyloid-beta (Ab) protein are a well-known 
pathology associated with AD. Although symptoms usually appear late in life, the 
accumulation of Ab begins decades earlier and causes activation of microglia, the brain’s 
immune cells. The ensuing inflammation contributes significantly to neurodegeneration. 
Determination of the particular form of Ab that causes the most damage in the brain is 
one of the major questions in the AD field. My research focused on the interactions of 
microglia with monomers, protofibrils, and fibrils of Ab. I found that protofibrils, not 
monomers or fibrils, bind to microglial surfaces, and I confirmed earlier reports that 
protofibrils elicit a proinflammatory response from microglia. These results were 
consistent regardless of changing conditions such as temperature, incubation time and Ab 
concentrations.  
Another aspect of my research was to investigate how microglia internalize 
different forms of Ab. The distinction between monomers and protofibrils may have 
  xii 
physiological significance in AD, yet there are few reports in the literature in which these 
two forms of Ab are examined separately. Monomers and protofibrils were carefully 
separated by size exclusion chromatography before cell treatments, which sets apart this 
work from research done in other labs. Multiple conditions and strategies, including a 
novel quantitation method for internalized Ab, demonstrated that microglia favor 
internalization of protofibrils over monomers. Further experiments determined that 
microglia are capable of internalizing protofibrils in high amounts without degradation. A 
significant amount of Ab protofibrils remain in the cytoplasm and are not routed to 
lysosomes, contradicting reports in the literature.  
A third research objective involves the study of microvesicles released from 
microglia. Microvesicles may have a role in AD by transporting Ab within the brain. I 
conducted experiments in which microglia were stimulated to produce microvesicles, and 
carried out assays to both confirm the presence of and visualize microvesicles. The 
studies described here contribute to the understanding of the interactions between 
microglia and Ab, potentially leading to a possible treatment or cure for AD. 
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CHAPTER 1: INTRODUCTION 
1.1 Alzheimer’s disease overview 
 As the number of people affected by Alzheimer’s disease (AD) continues to grow, 
investigations into the basic biochemistry and cellular aspects of this neurodegenerative 
disorder continue. Ultimately fatal, AD currently afflicts over 5 million people in the 
United States, and this number is expected to increase to 16 million by 2050, according to 
the Alzheimer’s Organization (March 2015 Fact Sheet). Tens of millions of people 
worldwide are victims of AD (World Health Organization), and this tally is expected to 
triple by 2050. 
 In most cases, AD manifests itself late in life, with loss of memory, difficulty 
recalling new information, and loss of intellectual abilities. These symptoms were 
associated with extracellular plaques of amyloid beta (Ab) and intraneuronal tau tangles, 
first described by Dr. Alois Alzheimer in 1907 (Stelzmann, et al., 1995). Yet, the buildup 
of Ab and tau begins decades before the manifestation of symptoms (Selkoe, 2011). 
While tau is an integral component of the disease process, the aggregation of Ab between 
brain cells precedes the formation of tau tangles within neurons (Selkoe and Hardy, 
2016). What follows is dysfunction in a variety of cell types in the brain (vascular cells, 
pericytes, astrocytes, oligodendrocytes, and neurons), including Ab clearance dysfunction 
and inflammation in microglia (discussed below), as a response to or consequence of Ab 
build-up in the brain (De Strooper and Karran, 2016). 
  2 
1.2 Amyloid beta 42 (Ab42) 
Ab is a peptide that is derived from a large transmembrane protein, up to 770 
amino acids in length, known as amyloid precursor protein [APP; (Wilkins and 
Swerdlow, 2016)]. The functions of APP include neuronal development, intracellular 
transport, signaling, and homeostasis (van der Kant and Goldstein, 2015). Figure 1.1A 
shows a schematic for APP with labels for the transmembrane domain as well as the sites 
of cleavage for a-, b, and g-secretases (Selkoe, 2011). Sequential cleavage by b-secretase 
then g-secretase results in the formation of the Ab peptide, which can be 36-42 amino 
acids in length (van der Kant and Goldstein, 2015). It is the 42-residue peptide that 
aggregates, causing the well-known pathology of intercellular plaques in AD (Jarrett, et 
al., 1993).  
The Ab42 monomer is a disordered peptide with a molecular weight of 4.514 
kDa. The amino acid sequence, shown in Figure 1.1B, is color-coded to show residue 
properties. The aggregation process shown in Figure 1.2 begins during the rate-limiting 
nucleation phase and is followed by assembly of the aggregation nuclei via non-covalent 
interactions (Jarrett, et al., 1993) to form soluble dimers, trimers and so on, which results 
in a solution of polydisperse soluble oligomers (Bitan, et al., 2003; Kayed, et al., 2003; 
Mittag, et al., 2014). Nucleation dependent polymerization is characterized by a lag 
phase, which is then followed by rapid aggregation (Jarrett and Lansbury, 1993). 
Subsequent steps lead to the formation of soluble protofibrils (Harper, et al., 1999; 
Mittag, et al., 2014; Walsh, et al., 1997, 1999) and insoluble fibrils(Harper, et al., 1997). 
The protofibril-to-fibril conversion can occur via monomer addition to protofibril ends,   
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Figure 1.1. Ab and APP.  (A) APP processing (Selkoe, 2011) (B) Ab42 schematic with 
one letter abbreviations for residues. 
 
 
  
A 
B 
  4 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Ab aggregation. Monomers are disordered peptides. The pathways which do 
not lead to aggregation (annulus, dodecamer, and amylospheroid) are distinct from the 
pathway which results in fibril aggregation via protofibrils. From Figure 1, 
Roychaudhuri, et al. (2009). 
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the joining of protofibril tips to one another, and lateral association of protofibrils 
(Harper, et al., 1999; Nichols, et al., 2002). Ab42 fibrils make up the dense cores of 
intercellular plaques (Terry, et al., 1964) with soluble Ab on the periphery of the plaques 
(Koffie, et al., 2009).  
Protofibrils are fibril precursors (Harper, et al., 1997; Walsh, et al., 1997) that 
have beta sheet structure (Nichols, et al., 2015; Walsh, et al., 1999). Though protofibrils 
are not as stable as fibrils (Kheterpal, et al., 2003; Walsh, et al., 1999), they resemble 
fibrils in thioflavin T (ThT) binding and circular dichroism (Walsh, et al., 1999). 
Protofibril lengths have been reported as <200 nm (Walsh, et al., 1997), and our 
measurements of protofibril lengths have been consistent with that, ranging from 50 ± 16 
nm to 78 ± 35 nm (Nichols, et al., 2015; Paranjape, et al., 2012). Reported diameters for 
protofibrils vary from 4-6 nm (Harper, et al., 1997). The hydrodynamic radius (RH) of 
protofibrils, measured by dynamic light scattering (DLS), has been reported to be 10-50 
nm (Walsh, et al., 1997), and our measurements of 21± 6 nm (Paranjape, et al., 2012), 
21.9 ± 4.0 nm (Paranjape, Terrill, and Gouwens, et al., 2013), and 23.6 ± 3.3 nm 
(Nichols, et al., 2015) fall into that range. Analyzed by SEC with in line multi-angle light 
scattering (MALS), protofibril molecular weights (MW) ranged from 200-2600 kDa, with 
an average of 884±302 kDa, (Nichols, et al., 2015). We are particularly interested in 
protofibrils because they have been shown to be toxic to neurons (Walsh, et al., 1999), 
disrupt ion channels (Ye, et al., 2003), and inhibit long-term potentiation in the 
hippocampus (O'Nuallain, et al., 2010). Additionally, results from our lab have shown 
that the soluble protofibrils of Ab42 are responsible for the activation of macrophages 
  6 
and microglia that results in the production of cytokines (Ajit, et al., 2009; Paranjape, et 
al., 2012; Paranjape, Terrill, and Gouwens, 2013).  
1.3 Microglia 
During early embryonic development, hematopoietic stem cells give rise to 
microglial cells, which migrate to the central nervous system [CNS, (Ransohoff and 
Cardona, 2010)]. Microglia are macrophages in the CNS, shaping neural circuits during 
development and throughout life (Banati and Graeber, 1994; Frost and Schafer, 2016; Ji, 
et al., 2013); Microglia are also involved in surveillance of the intercellular space, 
cleaning up dead cells and debris, and responding to threats (Kettenmann, et al., 2011). 
Activated microglia can be found near plaques in AD brain (McGeer, et al., 1987; Meyer-
Luehmann, et al., 2008), along with proinflammatory cytokines (Dickson, et al., 1993), 
and have been observed accumulating rapidly around new plaques (Meyer-Luehmann, et 
al., 2008).  
1.3.1 Inflammation and microglia 
The microglial inflammatory response, illustrated in Figure 1.3, is implicated in 
several CNS diseases (Frankola, et al., 2011). Though labeled “resting”, microglia use 
their many branches to actively read their surroundings (Kettenmann, et al., 2011). The 
exogenous signals that initiate inflammatory pathways, such as microbial infection, are 
pathogen-associated molecular patterns (PAMPs), which are molecular patterns not 
present in the host tissues (Tang, et al., 2012).  Pattern recognition receptors (PRRs) such 
as toll like receptors (TLRs) sense and respond to PAMPs, initiating cell signaling 
pathways in an attempt to mitigate the problem (Tang, et al., 2012). Similarly, when they 
sense danger-associated molecular patterns (DAMPS), which are endogenous signals  
  7 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Microglial activation and TNFa production (Frankola, et al., 2011).  
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indicating injury not related to an infection (Tang, et al., 2012), such as Ab, microglia 
become activated and produce proinflammatory cytokines, including tumor necrosis 
factor a (TNFa) and interleukin-1b (IL-1b) (Patel, et al., 2005). Chronic inflammation is 
thought to be partly responsible for neurodegeneration in AD, having a significant impact 
before symptoms appear (McGeer and McGeer, 1998). A variety of microglial receptors 
are involved in AD pathology. The receptors known to elicit proinflammatory responses 
when stimulated by fibrillar Ab include a complex of CD36, a6b1-integrin, and integrin 
associated CD47 (Bamberger, et al., 2003); CD14 (Fassbender, et al., 2004); toll-like 
receptor (TLR) 2 and TLR4 (Reed-Geaghan, et al., 2009); CD36 (El Khoury, et al., 2003; 
Moore, et al., 2002); and a CD36-TLR4-TLR6 complex (Stewart, et al., 2010). Others 
include complement receptors, Fc receptors that bind the constant domain of 
immunoglobin, formyl peptide receptors 1 and 2, receptor for advanced glycation end 
products, nod-like receptor protein, CD33, scavenger receptor A, and triggering receptor 
expressed by myeloid cells (Doens and Fernández, 2014). 
1.3.2 Cellular uptake of extracellular material 
Mammalian cells ingest materials by way of phagocytosis or pinocytosis. Figure 
1.4 provides an illustration of general mammalian cell uptake. Only pathogens and large 
particles are ingested through phagocytosis, which requires receptors. Of the five forms 
of pinocytosis, macropinocytosis does not require receptors. In this type of 
internalization, cell surface membranes produce waves, or ruffles, that extend into the 
extracellular space and then reconnect with the plasma membrane, bringing into the cell 
any particles that are in the surrounding medium (Conner and Schmid, 2003). 
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Figure 1.4 Mammalian cell uptake (Conner and Schmid, 2003). 
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Receptors known to be involved with Ab-microglial uptake of extracellular 
material include scavenger receptors (Paresce, et al., 1996); a complex of CD36, a6b1-
integrin, and CD47 (Koenigsknecht and Landreth, 2004); complement receptor 3 (CR3, 
Mac-1) signal regulatory protein b1 (SIRPb1) (Gaikwad, et al., 2009); and P2Y4 (Li, et 
al., 2013). Surface receptors such as toll like receptors (TLRs) have been shown to be 
involved in the activation of microglia as they interact with Ab42 (reviewed in Su, et al., 
2015). Mandrekar, et al. (2009) demonstrated that microglia take up soluble Ab via fluid-
phase macropinocytosis, which is not mediated by receptors. 
1.3.3 Internal trafficking of material in microglia 
 Most cells have lysosomes, acidic organelles that break down misfolded proteins 
and other unwanted material. Material can be routed to lysosomes through the pathways 
illustrated in Figure 1.5. Once ingested substances are internalized, they become part of a 
vesicle known as an early endosome (EE), which develops into a late endosome 
(LE)/multivesicular body (MVB). An alternative is that the LE becomes a recycling 
endosome (RE) which moves the material out of the cell. Some material will become part 
of the endolysosome (EL), which is formed when the LE/MVB fuses with a lysosome. 
Normally, unwanted material would be degraded within the acidic lysosome. As 
discussed in Chapter 4, this is not always the case for microglia interacting with Ab.  
1.3.4 Microglial P2X7 receptors 
 Characterized in 1996 (Surprenant, et al., 1996), P2X7 receptors are found in all 
types of immune cells, including microglia (Burnstock and Knight, 2004; Chen and 
Brosnan, 2006). With regard to AD, the presence of P2X7 receptors is increased in  
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Figure 1.5 Lysosomes (Luzio, et al., 2014) 
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 microglia near plaques in a mouse model of AD (Parvathenani, et al., 2003) and in 
human AD brains (McLarnon, et al., 2006; Takenouchi, et al., 2010). P2X7 receptors 
respond to ATP at millimolar concentrations, and at even lower concentrations for the 
agonist 2’,3’-(benzoyl-4-benzoyl)-ATP (BzATP) (Surprenant, et al., 1996). In response 
to ATP and/or LPS, microglia release inflammatory cytokines such as TNFa (Hide, et al., 
2000) and IL-1b (Brough, et al., 2002; Ferrari, et al., 1997; Rampe, et al., 2004). The 
cytokine release has been shown to occur through microvesicle production (Bianco, et al., 
2005).  
1.4 Microvesicles 
 An important aspect of intercellular communication is the release of membrane-
bound packets of cytoplasm from cells (Budnik, et al., 2016). These extracellular vesicles 
can be categorized by size and origin into two groups: exosomes are 30-100 nm in 
diameter and part of larger multi-vesicular bodies, and microvesicles are 100-1000 nm in 
diameter and form as buds from the cell surface (Budnik, et al., 2016). As shown in 
Figure 1.6 (top), microvesicles are complex, having varied receptors and cargoes. The 
budding process is also illustrated in Figure 1.6 (bottom), and of special interest for my 
work is the externalization of phosphatidylserine (PS), which can be used in experiments 
to verify the presence of microvesicles.  
Microvesicles have various roles outside of direct AD involvement. THP-1 
monocytes, immune cells in the bloodstream, release IL-1b via microvesicles 
(MacKenzie, et al., 2001). Microglia also release microvesicles carrying cytokines when 
stimulated with ATP (Bianco, et al., 2005). In 2009, Bianco and colleagues demonstrated  
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Figure 1.6 Microvesicles. Top: Structure. Bottom: formation from plasma membrane. 
Note the externalization of phosphatidylserine. (Hugel, et al., 2005)  
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the release of microvesicles from astrocytes and further showed that the mechanism 
proceeds through a p38 MAPK cascade and requires acid sphingomyelinase. Microglia-
to-neuron signaling was demonstrated by Antonucci, et al. (2012), and microvesicle 
stimulation of neuronal activity was shown by Turola, et al. (2012). The usefulness of 
microvesicles in identifying neuroinflammation caused by multiple sclerosis and 
measuring reduction of neuroinflammation through treatment was reported by Verderio, 
et al. (2012).  
With regard to microvesicles in AD, and from microglia in particular, there are 
interesting findings. Bianco, et al. (2005) demonstrated that microglia shed microvesicles 
when stimulated with ATP, and that the microvesicles contain the cytokine IL-1b. 
Microvesicles from microglia can interact with fibrillar Ab and convert it to a soluble and 
more toxic Ab form (Joshi, et al., 2014). Studies of human cerebrospinal fluid revealed 
that the combination of microvesicles and Ab42 is toxic to human brain cells and 
contributes to the spread of neurodegeneration through the AD brain (Agosta, et al., 
2014). The effect of microglial microvesicles on Ab42 aggregation and the role of 
microvesicles in Ab42 trafficking within and between cells are growing areas of research 
emphasis. Chapter 5 describes the work done to connect microvesicle production with Ab 
stimulation in microglia. 
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CHAPTER 2: METHODS 
2.1 Ab preparation 
 The Ab42 peptide used in my experiments was supplied by the same group under 
two different company names. They were known as the Large Scale Peptide Synthesis 
Laboratory in the W.M. Keck Biotechnology Resource Laboratory, Yale School of 
Medicine (Yale, New Haven, CT). In June, 2013, the lab ceased operation under that 
name, and in May of 2014 began work as the ERI Amyloid Laboratory, LLC (ERI, 
Oxford, CT). The ERI Amyloid Laboratory is our current Ab peptide supplier. Of the 
seven labeled preparations, the first three were from Yale, and the last 4 were from ERI. 
There were no significant differences between the peptide batches. The sequence and 
purity of all Ab peptide shipments were confirmed by mass spectrometry at ERI. 
2.1.1 Ab aliquot lyophilization 
Ab42 was obtained in lyophilized form and stored at -20 °C. Nucleation of 
amyloid proteins leads to rapid aggregation and occurs quickly in a concentrated solution 
(Jarrett and Lansbury, 1992), so dissociating any pre-formed Ab seeds is necessary to 
prevent aggregation. To prepare monomeric aliquots, the peptide was dissolved in 100% 
hexafluoroisopropanol (HFIP) (Sigma-Aldrich, St. Louis) at 1 mM and separated into 1 
mL aliquots in sterile, siliconized microcentrifuge tubes. The tubes were then left 
uncovered, at room temperature, overnight in a fume hood to evaporate the HFIP. On the 
following day, the aliquots were vacuum-centrifuged to remove any residual HFIP. A 
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thin film of Ab was deposited on the inside walls of the microcentrifuge tubes, which 
were then stored in dessicant at -20 °C.  
2.1.2 Preparation of Ab monomers, protofibrils, and fibrils 
A modified (without glucose) artificial cerebrospinal fluid (aCSF) was used to 
prepare Ab solutions. The composition of our aCSF is 15 mM NaHCO3, 1 mM Na2HPO4, 
130 mM NaCl, 3 mM KCl, pH 7.8. This aCSF solution was designed to mimic the ionic 
strength of cerebrospinal fluid and cell culture medium while leaving out the supplements 
that might interfere with spectroscopy and retaining the cell compatibility of growth 
medium (Paranjape, Terrill, and Gouwens, et al., 2013). The solution of Ab42 monomers 
and protofibrils was prepared by dissolving lyophilized Ab42 (1 mg) in 50 mM NaOH to 
yield a 2.5 mM Ab42 solution, which was then diluted to 250 µM Ab42 in prefiltered 
(0.22 µm) artificial cerebrospinal fluid. To allow protofibril formation, the Ab42 solution 
was incubated at room temperature for 30 min - 4 h. The wide range of incubation times 
was necessary as some of the aliquots required more time to form soluble aggregates. At 
this point, unlabeled Ab42 was purified by size exclusion chromatography (SEC) as 
described in 2.1.4 below. Peptide to be fluorescently labeled underwent the procedure 
described in 2.1.3. Fluorescently-labeled Ab4 fibrils were prepared by leaving monomer 
preps at 4 °C for two or more weeks; usually fibrils form after two weeks. 
2.1.3 Fluorescent labeling of Ab  
In some experiments with microglia, I conducted immunofluorescence assays to 
determine the location of Ab42 on or in treated cells (Paranjape, et al., 2012; Paranjape, 
Terrill, and Gouwens 2013). However, direct labeling with a fluorophore is a more 
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efficient method for tracking microglial interactions with Ab42. This strategy has been 
used by many research groups (for example, Fu, et al., 2012; Halle, et al., 2008; Li, et al., 
2012; Liu, et al., 2010; Mandrekar, et al., 2009; Paresce, et al., 1997). Alexa Fluor® 488 
carboxylic acid, 2,3,5,6-tetrafluorophenyl ester (AF488-TFP, Life Technologies) is an 
amine-reactive fluorophore that has been used to label soluble oligomers of Ab42 
(Jungbauer, et al., 2009). The structure of AF488-TFP is shown in Figure 2.1. In their 
experiments, Jungbauer and colleagues compared oligomers labeled before aggregation 
to oligomers labeled after aggregation. Their work showed that allowing the peptide to 
aggregate before conducting the labeling experiment, rather than labeling monomers first 
and allowing them to aggregate, produced soluble, labeled Ab oligomers that are most 
similar to unlabeled Ab oligomers. Therefore, I used a solution containing both 
monomers and protofibrils, prepared as described above, for the labeling reaction.  
Attaching a fluorescent label directly to the peptide had several advantages. The 
direct fluorescence meant that I could visualize Ab42 both on and in cells without the 
risk of non-specific interactions between antibodies and non-target proteins. The strength 
of the fluorescence allowed visualization of Ab42 even at low concentrations of 0.5, 1 
and 2 µM. Less time was required for completing experiments, and I had the option of 
imaging live cells.  
There are three primary amine groups in the Ab42 monomer which can 
potentially interact with AF488-TFP: lysine-16, lysine-28, and the N-terminus. Each of 
these is a nucleophile that can attack the carbonyl carbon located between the 
tetrafluorophenyl group and the fluorophore of A488-TFP. The reaction mechanism for 
the Ab N-terminal amine is shown in Figure 2.2. 
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Figure 2.1 Structure of Alexa Fluor ® 488 tetrafluorophenyl ester (Life Technologies). 
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Figure 2.2 Labeling reaction mechanism for Ab and amine-reactive AF488-TFP. I drew 
this mechanism using ChemDoodle® software (Version 7.0.1, iChemLabs.) 
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The manufacturer’s protocol calls for dissolving the protein to be labeled in 1 mL 
of sodium bicarbonate buffer pH 8.3, dissolving the dye in dimethylsulfoxide or  
dimethylformamide at 10 mg/mL, and then combining the two solutions. A conversation 
with an Invitrogen support technician confirmed that if the pH was 8.0 or higher, the 
labeling reaction would proceed in our aCSF buffer. The NaOH/aCSF solution in which 
the peptide was prepared has a pH of 8.2. 
To conduct the labeling reaction, 500 µL of an Ab42 solution with both 
protofibrils and monomers was added to 100 µg of AF488-TFP dry powder in the 
original tube from the manufacturer, mixed gently by pipet, and transferred to a 1.8 mL 
glass vial containing a 5-mm magnetic stir bar. A second 500 µL volume of Ab42 
solution was added to the original tube to capture any remaining powder, then transferred 
to the glass vial. The Ab/AF488-TFP mixture was gently stirred for 1 h at 25°C. After 
stirring, the solution was transferred to a siliconized microcentrifuge tube prior to 
chromatographic separation. 
2.1.4 Size exclusion chromatography (SEC) 
 Before SEC, the AF488-Ab monomer+protofibril solution underwent 
centrifugation at 17,000 x g for 10 minutes to pellet any non-soluble fibrils that may have 
formed. Both unlabeled and fluorophore-labeled Ab42 centrifugation supernatants were 
fractionated on a Tricorn Superdex 75 10/300 GL column (GE Healthcare) using an 
AKTA FPLC system (GE Healthcare). Prior to injection of the Ab42, the Superdex 75 
column was coated with sterile bovine serum albumin (Sigma) to prevent any non-
specific binding of Ab42 to the column matrix. 1 mL of the sample was loaded, either 
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Ab42 or AF488-Ab was eluted at 0.5 mL min-1 in aCSF, and 0.5 mL fractions were 
collected and immediately placed on ice. Elution was monitored in-line by UV 
absorbance (A280), and concentrations of unlabeled Ab42 were determined from these 
absorbance values. A representative UV trace, combined with fraction fluorescence 
measurements, for AF488-Ab is shown in Figure 2.3. AF488-Ab42 concentrations were 
determined as described below in Section 2.2.3. Shana Terrill-Usery, Sanjib Karki, Ben 
Colvin, and Nyasha Makoni all assisted me with SEC. 
2.2 Characterization of fluorescently labeled Ab 
2.2.1 Fluorescence measurements 
 AF488 has a maximum emission at 525 nm (Life Technologies). Measuring the 
fluorescence of each 0.5 mL fraction which can be used to confirm labeling success. If 
the fluorescence of the fractions lines up with the peaks on the inline trace then it is 
reasonable to assume that the labeling was successful. AF488-labeled Ab42 fluorescence 
in SEC fractions was determined using a Cary Eclipse fluorescence spectrophotometer. 
Emission scans of 500-600 nm were obtained with an excitation wavelength of 495 nm. 
The resulting curves were integrated from 505-550 nm to produce relative fluorescence 
units (RFU), shown in Figure 2.3 as red circles. The integrated fraction fluorescence 
values align well with the SEC trace peaks, which confirms the association of the 
fluorophore with the peptide. 
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Figure 2.3 Representative UV trace for SEC elution overlaid with fluorescence 
measurements of fractions. SEC trace (blue line) and fraction fluorescence (red circles) 
showing peaks for protofibrils, monomers, and unincorporated AF488-TFP (AF dye). 
(Gouwens, et al., 2016) 
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2.2.2 Absorbance measurements 
An inline UV trace identified the fractions containing Ab42. For unlabeled Ab42, 
this trace is used to determine the concentration of peptide in each fraction. However, the 
inline UV overvalued the concentrations in each fraction of AF488-Ab because the   
AF488 fluorophore absorbs at 280 nm. Manual measurements of UV absorbance were 
taken to use in calculations. AF488-Ab chromatography samples were scanned from 600 
to 220 nm on a Cary 50 (Varian) UV/Visible spectrophotometer. Figure 2.4 contains a 
representative scan of a fraction containing unincorporated AF488-TFP in aCSF that is 
typical of the seven labeled preps. The large peak near 500 nm is due to the fluorophore, 
Ab42 has no absorbance at those wavelengths. A low amount of absorbance is visible at 
280 nm (0.1 AU), and because of that I needed to calculate AF488-Ab concentrations 
(see Section 2.2.3). Confirmation that using the manual absorbance measurements for 
calculations would be accurate came from comparing the A280 manual measurements to 
the inline UV absorbance, as is shown in Figure 2.5. Absorbance measurements of peak 
fractions (red circles) of protofibril, monomer, and unreacted AF488-TFP all fall on the 
line obtained from the inline trace (blue line). This indicates that both methods of 
assessing UV absorbance agree.  
2.2.3 Ab concentration calculations 
Since Ab42 and the AF488 label both contribute to total absorbance (A280, tot), 
AF488-Ab42 concentrations were obtained after subtraction of the fluorophore 
absorbance at 280 nm (A280, AF488) from A280, tot. The contribution of AF488 to A280, tot is 
described by the relationship A280, AF488 = A494, AF488 x 0.11, where A494, AF488 is the 
absorbance of the fluorophore at 494 nm (Life Technologies). Concentrations of AF488- 
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Figure 2.4 AF488 absorbs at 280 nm. The large peak at 494 nm is due to the 
unconjugated AF488 fluorophore. The absorbance at 280 nm is equal to 11% of the 
absorbance at 494 nm. 
 
 
  
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
220 280 340 400 460 520 580
Ab
so
rb
an
ce
,	A
U
Wavelength,	nm
Unincorporated	AF488-TFP	in	aCSF
  25 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Comparison of UV-Vis absorbance measurement methods. Absorbance values 
at 280 nm measured by SEC inline UV (blue line) and manual UV spectrophotometry of 
0.5 mL fractions (red circles). Representative data from one of the seven labeled preps. 
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Ab in sample preparations were determined using A494, AF488 and A280, tot from the 
absorbance scans and the following calculation derived from Beer’s Law (A = e l c):  
CAF488-Ab = [A280, tot – (A494, AF488 x 0.11)] ÷ [e280, Ab x l]  (Equation 1) 
where l is the path length (1 cm) and e280, Ab is the extinction coefficient at 280 nm for Ab 
1450 M-1 cm-1 (Nichols, et al., 2002). Unincorporated AF488-TFP concentrations were 
determined using an extinction coefficient at 494 nm of 71,000 M-1 cm-1 (Life 
Technologies). The AF488:Ab42 stoichiometry was then obtained. Table 2.1 provides a 
summary of the labeling stoichiometry of peak protofibril and monomer fractions. In 
protofibrils, lysine-16, lysine-28, and some N-termini may not be accessible to the 
fluorophore, so it was expected that there would be a lower labeling stoichiometry for 
protofibrils than monomers. For the seven AF488-Ab42 preparations used in my 
experiments, the average AF488:Ab42 ratio was 0.14 ± 0.03 for protofibrils, and 0.50 ± 
0.08 for monomers. The three-fold higher stoichiometry of labeling for monomers was 
meaningful for data interpretation. 
2.2.4 Electron microscopy 
SEC-purified Ab solutions, both labeled with Alexa Fluor® and unlabeled, 
containing protofibrils or fibrils (10 µL) were applied to a 200-mesh Formvar-coated 
copper grid (Ted Pella, Inc.) Samples were allowed to adsorb for 10 min at 25 °C, 
followed by removal of excess sample solution. Grids were washed three times by 
placing the sample-containing side of the grid down on a droplet of water. Heavy metal 
staining was done by incubation of the grid, sample side down, on a droplet of 2% uranyl 
acetate (Electron Microscopy Services, Hatfield, PA) for 5-10 min, removal of excess  
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Table 2.1 Stoichiometry of protofibrils and monomer peak fractions. Average 
fluorophore:protofibril = 0.14 ± 0.03. Average fluorophore:monomer = 0.50 ± 0.08. 
Calculated as described in Methods 2.2.3. 
 
PROTOFIBRILS MONOMERS 
Prep Fluor., µM Ab, µM Fluor:Ab Prep Fluor., µM Ab, µM Fluor:Ab 
1 4.1 37 0.11 1 19 51 0.37 
2 3.9 45 0.09 2 22 58 0.38 
3 3.4 47 0.07 3 13 27 0.48 
4 3.7 26 0.14 4 17 50 0.34 
5 4.6 32 0.14 5 20 39 0.51 
6 3.9 20 0.20 6 16 25 0.64 
7 4.3 18 0.24 7 21 28 0.75 
 
 
 
  
  28 
solution, and air drying. Affixed samples were visualized by Dr. David C. Osborn with a 
JEOL JEM-2000 FX transmission electron microscope operated at 200 keV. 
Visualizing the AF488-Ab42 protofibrils with transmission electron microscopy 
allowed me to verify that they had the same length and curvilinear morphology as the 
unlabeled Ab42 protofibrils. Figure 2.6 shows the similarities between both labeled and 
unlabeled Ab42 protofibrils and fibrils. While the AF488-Ab concentration (38 µM) used 
for preparing the TEM grid makes for a crowded image (Panel B), the morphology of the 
protofibrils is unmistakable (compare Panels A and B) and was not affected by the 
attachment of the fluorophore. Similarly, the label did not affect aggregation, as 
monomers were able to aggregate into fibrils. The image shows fibrils formed from 
monomers after 53 days at 4 °C, but fibrils formed in other labeled monomer samples in 
as little as two weeks at 4 °C.  
2.2.5 Dynamic light scattering 
 Hydrodynamic radius (RH) measurements of Ab protofibrils, and of 
microvesicles, were made at room temperature with a DynaPro Titan instrument (Wyatt 
Technology, Santa Barbara, CA). Samples (30 µL) were placed directly into a quartz 
cuvette and light scattering intensity was collected at a 90° angle using a 10-s acquisition 
time. Particle diffusion coefficients were calculated from auto-correlated light intensity 
data and converted to RH with the Stokes-Einstein equation. Average RH values were 
obtained with Dynamics software (version 6.7.1). Histograms of percent intensity vs. RH 
were generated by Dynamics data regularization, and intensity-weighted or mass-
weighted mean RH values were derived from regularized histograms. Figure 2.7  
 
  29 
 
 
 
Figure 2.6 Transmission electron micrographs of unlabeled Ab42 and AF488-Ab42. (A) 
Unlabeled protofibrils, 10 µM; (B) AF488-protofibrils, 38 µM; (C) Fibrils formed from 
unlabeled monomers, 10 µM; (D) Fibrils formed from AF488-monomers, 37 µM. A and 
C scale bars = 100 nm (Paranjape, Terrill, and Gouwens, et al., 2013); B and D scale bars 
= 50 nm (Gouwens, et al., 2016).   
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demonstrates the similar hydrodynamic radii for both unlabeled Ab and AF488-Ab 
protofibrils. The mean RH for unlabeled protofibrils (average of five preps) formed in 
aCSF was reported as 21.9±4.0 nm (Paranjape, Terrill, and Gouwens, et al., 2013) and for 
AF488-Ab protofibrils formed in aCSF the mean RH = 16 nm, range = 5-50 nm 
(Gouwens, et al., 2016). While I have conducted DLS measurements for other 
investigations, the measurements of Ab42 were made by Dr. Nichols and we discussed 
the data.  
 DLS was also used to determine microvesicle size. Again, measurements were 
made by Dr. Nichols and there were subsequent discussions of the data. Microvesicle 
characterization by DLS is discussed in Section 5.1.3 of Chapter 5. 
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Figure 2.7 Dynamic light scattering (DLS). Protofibrils were analyzed by DLS 
immediately after SEC isolation. Representative regularized histograms of percent 
intensity vs. hydrodynamic radius are shown. Left: Histogram for unlabeled protofibrils 
prepared in aCSF, mean RH = 23 nm (Paranjape, et al., 2013). Right: Histogram for 
AF488-protofibrils in aCSF, mean RH = 16 nm (Gouwens, et al., 2016).  
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2.3 Cell Culture 
2.3.1 BV-2 microglia culture 
 BV-2 cells are an immortalized murine microglial cell line derived from primary 
murine microglia by stable transfection with the J2 virus, a v-raf/v-myc oncogene-
carrying retrovirus (Blasi, et al., 1990). Our BV-2 cells were provided by Dr. Gary 
Landreth, Case Western Reserve University, and were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, 4.5 g/L glucose, Hyclone) containing 50 U/mL 
penicillin, 50 µg/mL streptomycin, 50 µM b-mercaptoethanol, and 5% heat inactivated 
fetal bovine serum (FBS, Hyclone) in 75 cm2 flasks (Corning). BV-2 cells were used for 
their ease of culture, to make initial observations comparing them to primary cells, and 
for the optimization of microglia-Ab interactions. After thawing, 1.5 mL BV-2 cells (1e6 
cells/mL) are added to 5 mL growth medium and centrifuged at 500xg for 7 min. The 
supernatant is removed by vacuum aspiration, then the cell pellet is resuspended in 10 
mL growth medium and the cell solution is added to a T75 cell culture flask (Corning).  
Cells are passaged twice weekly as follows. Growth medium is removed and, 
after rinsing with 1 mL sterile PBS, 1 mL 0.25% Trypsin (Sigma) is added to the flask to 
dislodge adherent cells from the bottom of the flask. The cells are then incubated for 7 
min at 37 °C. 9 mL of growth medium is added to the flask, and from that volume 3 mL 
are transferred to a 15-mL conical tube, which is centrifuged at 500xg for 7 min. For the 
first passage after thawing, 3 mL are spun down, and for the second passage 1 mL is spun 
down. The amounts centrifuged will then alternate between 3 mL and 1 mL in order to 
keep the BV-2 concentration at an optimal level.  
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2.3.2 Primary microglia isolation and culture 
 Primary murine microglia were obtained from wild-type (WT) C57BL/6 (Harlan 
Laboratories). Care and breeding of the C57BL/6 parent mice were done at the University 
of Missouri-St. Louis Animal Facility. Isolation of microglia was conducted as described 
in Esen and Kielian (2007) and Paranjape et al. (2012). 3-4-day-old mouse pups were 
euthanized with an overdose of inhaled isoflurane (Fisher Scientific). Brains were 
isolated and meninges were removed under sterile conditions. Brain tissue was minced 
using sharp-edged forceps, resuspended in 0.5% trypsin (Hyclone), and incubated at 37 
°C with shaking for 20 min to allow further dissociation of the tissue. Subsequently, the 
tissue was resuspended in complete DMEM containing 10% FBS, 4 mM L-glutamine, 
100 U/mL penicillin, 0.1 mg/mL streptomycin and 0.25 µg/mL amphotericin-B (Fisher 
Scientific), OPI medium supplement (oxaloacetate, pyruvate, insulin, Sigma), and 0.5 
ng/mL recombinant mouse granulocyte-macrophage colony-stimulating factor (GM-CSF, 
Invitrogen). The cell suspension was further triturated using a pipet and filtered through a 
70 µm cell strainer to remove debris. The resulting cell suspension was centrifuged at 
200g for 5 min at 25 °C, resuspended in complete medium, and seeded into 150 cm2 
flasks (Corning). Cells were cultured at 37 °C in 5% CO2 until confluent (1-2 weeks), and 
microglia were selectively harvested from the adherent astrocyte layer by shaking at 250 
rpm for 5 h in 5% CO2 at 37 °C followed by collection of the medium. (For isolations 
done before 2016, the flask was shaken overnight at 37 °C in 5% CO2.) The flasks were 
replenished with fresh medium and then incubated further to obtain additional microglia. 
Typically, this procedure was repeated 3-4 times for one flask without removal of the 
astrocyte layer. In the bulk of the experimentation, primary microglia were isolated by 
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Geeta Paranjape, Shana Terrill-Usery, Sanjib Karki, Ben Colvin, or Nyasha Makoni, and 
I handled the care, preparation, plating, treatment, and analysis of the cells for 
experiments. 
2.4 Microglial AF488-Ab uptake experiments 
2.4.1 Ab treatment for ELISA and confocal LSM analysis 
 For cell uptake studies, WT primary murine microglia, acquired as described 
above, were seeded on glass coverslips, in sterile glass-bottom Mat-Tek P35GC-1.5-14-C 
culture dishes (Mat-Tek Corp., Ashland, MA) or 96-well cell culture plates at a density of 
5 x 105 cells/mL in complete growth medium (volumes of 0.200 mL, 0.200 mL and 0.100 
mL, respectively). Prior to cell treatment, growth medium was replaced with assay 
medium (growth medium lacking FBS and GM-CSF). Lysosome labeling was done prior 
to cell treatment by adding 0.100 mL assay medium containing 0.100 µM LysoTracker® 
Red DND-99 (Invitrogen) and incubating for 30 min at 37 °C in 5% CO2. For treatment 
times >6 h, LysoTracker® was added to the assay medium 30 min before treatment 
ended. Cells were then incubated at 37 °C in 5% CO2 with AF488-labeled Ab (AF488-
Ab), unlabeled Ab42, aCSF control, or AF488 dye fraction. Times of incubation and 
concentrations of AF488-Ab, unlabeled Ab and AF488 dye are noted in figure legends. 
Following incubation, the conditioned medium was collected and stored at -20 °C for 
subsequent analysis by enzyme-linked immunosorbent assay (ELISA) or immuno-dot 
blot. Adherent microglial cells were rinsed 3X with 0.05% Tween 20 in phosphate 
buffered saline (PBST) and then fixed with 3.7% formaldehyde for 15 min. Fixed cells 
were stored overnight at room temperature in the dark before confocal microscopy 
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analysis. Microglia were seeded on glass coverslips by placing a 100-200 µL drop of cell 
suspension in the middle of the coverslip, which was in a 30 mm culture dish. A lid was 
placed over the culture dish to prevent evaporation during incubation. Microglia were 
able to adhere to the coverslip, Medium changes were accomplished by placing a pipet 
tip at the edge of the droplet and removing the liquid. Treatment was applied by gently 
adding 100 µL to the area of the coverslip occupied by the microglia. After fixing for 
immunofluorescence or direct fluorescence, followed by staining of the nuclei, the 
coverslip was placed upside-down over a 50-µL droplet of PBS or ProLong Gold 
Antifade Mountant (Thermo Fisher Scientific) on a microscope slide. 
2.4.2 Ab treatment for fluorescence plate reader and dot blot analysis 
 Primary WT murine microglia were plated in Nunc F96 Nunclon sterile 96-well 
black plates at a density of 5 x 105 cells/mL in complete growth medium (0.1 mL 
volume). Times of incubation and concentrations of AF488-Ab, unlabeled Ab are noted 
in figure legends. In order to remove Ab from the cell surface membranes, a more 
thorough wash protocol was utilized for these studies. Medium was removed from treated 
cells and placed in clean wells in the plate. Each cell-containing well was rinsed 3X with 
100 µL sterile PBS. An acid wash (100 µL) was performed using a solution of 0.5 M 
NaCl and 0.2 M acetic acid for 15 minutes at 4 °C, then cells were rinsed 2X with PBS. 
All PBS and acid washes were moved to either clean wells or another plate for both 
fluorescence and dot blot analysis. 
 For intracellular extract preparation, microglia were lysed for 15 min at 25 °C 
with 35-50 µL radio immunoprecipitation assay (RIPA) buffer containing 150 mM NaCl, 
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20 mM Tris, 1 mM ethylenedaminetetraacetic acid (EDTA), 1% Triton X-100, 1% 
deoxycholic acid, 0.1% sodium dodecyl sulfate (SDS), and protease inhibitor cocktail 
(Sigma) at a 10X dilution. In some cases, multiple microglia wells were combined to 
yield higher concentration lysates. Microglial lysates were stored at -20 °C for further 
analysis. 
2.4.3 BV-2 microglia cell binding assay 
BV-2 microglia were removed from culture flasks with 0.25% trypsin. Cells were 
counted using a Cellometer® (Nexcelom Bioscience), pelleted by centrifugation at 500xg 
for 7 min, and resuspended at a concentration of 5 x 105 cells/mL. 0.2 mL cells were 
seeded in sterile glass-bottom Mat-Tek P35GC-1.5-14-C culture dishes (Mat-Tek Corp., 
Ashland, MA) at a density of 5 x 105 cells/mL in assay medium (growth medium lacking 
FBS). Prior to cell treatment, adherent cells were rinsed once with assay medium. Cells 
were treated with AF488-Ab or unlabeled Ab42 (concentrations indicated in figure 
legends) and then incubated at 4 °C, room temperature, or 37 °C in 5% CO2 for 30 min. 
BV-2 cells were rinsed 3X with 0.05% Tween 20 in phosphate buffered saline (PBST) 
and then fixed with 3.7% formaldehyde (15 min, room temperature) for confocal 
microscopy analysis. BV-2 microglia treated with unlabeled Ab underwent the 
immunofluorescence assay described in Section 2.6. 
 2.5 Fluorescence quantitation for AF488-Ab-treated microglia 
To quantitate AF488-Ab internalization, in situ cellular fluorescence 
measurements were carried out using a Perkin Elmer Victor 3 multi-mode plate reader. 
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Excitation and emission filters were 485 nm and 535 nm, respectively, with a 0.1 second 
signal averaging time.  
The first experiments I conducted using a black plate and the plate reader 
employed BV-2 cells treated with AF488-Ab. While the data (not shown) indicated some 
concentration-dependent differences in the fluorescent signal, the signal-to-noise ratio 
was small, and there was no way to determine if the fluorescence was from Ab inside the 
cells, on the cells, or both. The use of an acid wash, 0.5 % NaCl and 0.2 % acetic acid, to 
remove antibodies on cell surfaces was reported in 2007 (Liu, et al., 2007) and I used this 
wash for primary cells treated with AF488-Ab. First, a “proof of concept” experiment 
was done to assess the ability of a plate assay to measure uptake. Primary microglia were 
treated with 5 µM AF488-Ab monomers or protofibrils (3 wells each), 5 µM unlabeled 
Ab42 monomers or protofibrils (3 wells each), 1 µM AF488-Ab protofibrils (3 wells) 
and aCSF control (3 wells). The plate was incubated for 30 min at 37 °C, 5% CO2. After 
transferring the assay medium to clean wells, there were three washes with PBS (100 µL 
per well), then the acid wash (100 µL per well), and two more washes with PBS 
followed. All washes were transferred to clean wells. Because of this extensive washing 
including the acid wash, the fluorescence measured in the cell-containing wells reflects 
only internalized AF488-Ab. Figure 2.8 shows the fluorescence intensity readings 
measured by plate reader. Negligible fluorescence intensity was measured in the cells 
treated with unlabeled Ab42 and the control wells. The lack of fluorescence intensity 
difference between AF488-Ab42 monomer and protofibril treated cells is not what I 
usually see. Monomer-treated cells are expected to have less fluorescence than 
protofibril-treated cells. The AF488-Ab42 was about two weeks post-purification,   
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Figure 2.8 Plate reader fluorescence, AF488-Ab. Representative data showing 
fluorescence from a microglia treatment experiment. The fluorescence in the cells is what 
remains after acid washing. Fluorescence in the acid wash wells represents AF488-Ab 
removed from outer cell membrane surfaces. Inset: Fluorescence in cells after washes. 
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though, and so had already begun to aggregate. There is a difference between the 1 µM 
and 5 µM AF488-Ab42 protofibril-treated wells, so from this I knew this assay was 
sensitive enough to measure uptake differences in concentration and could probably be 
used in time dependent experiments. It was advantageous to measure uptake this way 
since using the 96-well plates allowed for more treatment conditions and replicates 
without using more reagents – especially AF488-Ab – and plate reader measurements 
were less time-consuming and more objective than quantitating fluorescence images. 
2.6 Immuno-detection of Ab and confocal microscopy 
2.6.1 Preparation of fixed cells for microscopy 
BV-2 and primary murine microglial cells were stimulated, treated and fixed as 
described above (Section 2.4.1). Cell samples were then washed 3X with PBST. Cell 
nuclei were visualized by incubation for 5 min with 0.2 mL of 0.3 µM 4’,6-diamidino-2-
phenylindoledihydrochloride (DAPI). After a final wash step, 1-2 mL PBS was applied to 
the Mat-Tekä dishes to avoid cellular dehydration. In some cases, ProLong Gold 
Antifade (Thermo Fisher Scientific) was applied, the well was covered with a glass 
coverslip and the antifade mountant was allowed to set overnight. Microglia treated with 
AF488-Ab were imaged directly without further manipulation.  
For microglia treated with unlabeled Ab42, fixed cells were incubated for 1 h 
with blocking buffer (10% w/v dried milk in PBST). Samples were washed 3X with 
PBST after this step and each subsequent step. All incubations were conducted with 
gentle shaking at 25 °C. After blocking, samples were incubated for 1 h with the anti-Ab 
antibody Ab9 (1:5000 dilution in PBST with 5% w/v dried milk) followed by a 1 h 
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incubation with donkey anti-mouse IgG antibody conjugated to Northern Lights (NL) 
493 (R&D Systems).  
Lysosomal Lamp1 detection was done by immunostaining in a manner similar to 
that for unlabeled Ab. After incubating for 1 h in a blocking buffer of PBS containing 1% 
bovine serum albumin (BSA) with gentle shaking, the cells were rinsed 3X with PBST. 
Next, a 1:500 dilution of anti-Lamp1 primary antibody (Novus Biologicals) into PBS 
containing 1% BSA and a 1:100 dilution of anti-mouse IgG-NL637 secondary antibody 
(R&D Systems) into PBS containing 1% BSA were each incubated for 1 h with gentle 
shaking and rinsed 3X with PBST. After a final wash step, cell nuclei were 
counterstained with DAPI and 1 mL PBS was applied to the wells to avoid cellular 
dehydration.  
2.6.2 Confocal microscopy 
The light coming from a specimen in confocal microscopy is controlled by a 
pinhole so that its source is limited to a single plane through the specimen. The resulting 
image is therefore of a slice through the cell. Any visible fluorescence is from a 
fluorophore within that plane of the cell, not above or below. In addition, when multiple 
fluorophores are used, channels can be used, as shown in Figure 2.9B, so that only 
particular wavelengths are collected during a scan. During the next scan of the same 
plane, another set of wavelengths can be collected. This prevents crosstalk resulting from 
the emitted light of one fluorophore exciting another fluorophore. If that happened, the 
recorded light emission that would be incorrectly attributed to the first fluorophore. For 
the work reported herein, the signal from each fluorophore was collected individually. 
Both two-dimensional and Z-stack images were obtained with a Zeiss LSM 700   
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Figure 2.9 Confocal laser scanning microscopy. TOP: Light beam path. Light emission is 
captured point by point, and the light reaching the detector is limited by the pinhole 
before it reaches the detector. BOTTOM: Light collection channels. Collecting light in 
only one part of the spectrum at a time limits cross-talk. The setting used most often for 
the images in my research is the second, where each part of the spectrum is collected 
separately. (From Carl Zeiss LSM 700 Operating Manual, September 2011) 
  
  42 
confocal microscope at 40X magnification using ZEN 2009 imaging and analysis 
software. Excitation wavelengths used were 405 nm (DAPI), 488 nM (AF488-Ab42 and 
anti-mouse IgG-AF488 secondary antibody), 561 nm (LysoTracker® Red, Invitrogen), 
and 639 nm (antimouse IgG-NL637 for Lamp1, R&D Systems). For comparison 
experiments, all optical and electrical settings were fixed at identical levels for each 
image to ensure that fluorescence intensity measurements were not influenced by 
different settings.  
Confocal fluorescence images were quantitated with ImageJ software (NIH) using 
a procedure detailed by Ansari, et al. (2013). Briefly, a region of interest was drawn 
around each cell using a polygon drawing tool. Area and integrated density were 
measured for each cell using ImageJ. Background fluorescence was measured by 
averaging five random areas between cells in the field. The corrected total cell 
fluorescence (CTCF) was calculated as follows: [integrated density of total cell area – 
(total cell area x mean background fluorescence)].  
A second method of quantitation involved selecting the channel for fluorescence 
produced by AF488-Ab, changing the color presentation to grayscale, and measuring 
integrated fluorescence intensity using ImageJ. Integrated density was divided by the 
number of cell nuclei in the field. Excel was employed to compile the data from separate 
experiments and calculate error. These two methods were used for experiments in which 
the plate reader assay described in Section 2.5 was not used.  
2.7 Immuno-dot blot 
 A nitrocellulose membrane was soaked in water and allowed to dry completely. 
Microglial cell lysates (1.7 µL) were spotted onto the membrane and allowed to dry for 
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20 min. Subsequent incubation and washing steps were carried out with gentle shaking 
(70 rpm on a rotary platform shaker) at 25 °C. The membrane was placed in a blocking 
buffer of phosphate buffered saline (PBS) containing 0.1% Tween-20 and 5% dry milk 
and incubated for 1 h, followed by washing 3X for 5 min with PBS containing 0.2% 
Tween-20, pH 7.4 (0.2% PBST). Incubation for 1 h in a 1:5000 dilution of mouse anti-
Ab primary antibody Ab9 in PBS containing 1% dry milk and 0.1% Tween-20 was 
followed by incubation for 1 h in a 1:1000 dilution of anti-mouse IgG-HRP secondary 
antibody in the same buffer. The wash steps detailed above were done after the primary 
and secondary antibody incubations. The nitrocellulose membrane was then treated with 
ECL western blotting substrate solution (Pierce) and washed for 1 min with accelerated 
shaking at 120 rpm. After drying, the membrane was exposed to film for 60 secs in an 
autoradiography cassette. The film was developed, fixed, washed in water and dried for 
scan analysis. Duplicate dot blot membranes were probed for GAPDH as a control 
intracellular protein. The procedure differed only in the primary antibody, using mouse 
anti-GAPDH antibody (1:1000 dilution). Densitometry was performed on dot blot film 
images using ImageJ software (NIH). Victoria A. Rogers and Nyasha J. Makoni 
performed the immuno-dot blot analyses. 
2.8 ELISA 
 Measurements of tumor necrosis factor a (TNFa) were done by enzyme-linked 
immunosorbent assay (ELISA). 96-well plates (Nunc, Fisher Scientific) were coated with 
100 µL per well of 4 µg/mL monoclonal anti-mouse TNFa capture antibody (R&D 
Systems) and incubated overnight at 25 °C. 100 µL of 4 µg/mL monoclonal anti-mouse 
TNFa capture antibody (R&D Systems), washed with PBS containing 0.5% Tween-20 
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and blocked with PBS containing 1% bovine serum albumin (BSA), 5% sucrose and 
0.05% NaN3 followed by a wash step. Successive treatments with washing in between 
were done with samples or standards, biotinylated polyclonal anti-mouse TNFa detection 
antibody (R&D Systems in 20 mM Tris with 150 mM NaCl and 0.1% BSA, streptavidin-
horseradish peroxidase (HRP) conjugate, and equal volumes of HRP substrates 3,3’,5,5’-
tetramethylbenzidine and hydrogen peroxide. The reaction was stopped by the addition of 
1% H2SO4 solution. The optical density of each sample was analyzed at 450 nm with a 
reference reading at 630 nm using a SpectraMax 340 absorbance plate reader (Molecular 
Devices, Union City, CA). The concentration of TNFa in the experimental samples was 
calculated from a mouse TNFa standard curve of 15-2000 pg/mL. When necessary, 
samples were diluted to fall within the standard curve. 
2.9 Microvesicle generation and isolation from BV-2 and primary microglia  
 BV-2 microglia seeded into a T-150 flask (Fisher) were cultured to confluence. 
The growth medium was then removed, and the cells were rinsed once with sterile PBS, 4 
mL per flask. The PBS was removed and 4 mL aCSF was added to the control flask while 
4 mL aCSF with 1 mM ATP was added to the treatment flask. Both flasks were incubated 
at 37 °C in 5% CO2 for 10 minutes. The aCSF was removed and transferred to a labeled 
15-mL conical tube to be centrifuged at 2000xg for 20 mins (Crescitelli, et al., 2013). 
Pellets formed in that spin contain apoptotic bodies or even whole cells, but the 
microvesicles are soluble and will remain in the supernatant. The supernatant is collected, 
distributed into four labeled 1.5 mL microcentrifuge tubes, 1 mL each, and 3.8 µL 2-(6-
(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)haxanoyl-1-hexadecanoyl-sn-glycero-3-
phosphocholine (NBD C6-HPC) was added to each tube (final [NBD C6-HPC] = 10 
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µM). Tubes were then centrifuged at 12,200xg for 40 mins to pellet the microvesicles 
(Crescitelli, et al., 2013). Supernatants were removed and kept for further analysis. One 
of the pellets was reconstituted in 200-500 µL aCSF, then the entire volume was 
transferred to the second tube to reconstitute another pellet. This process was repeated for 
all four tubes to resuspend and concentrate the microvesicles in one volume.  
The amount of primary microglial cells available was limited, and so control 
experiments in which cells did not receive ATP treatment were not done. Co-cultures of 
astrocytes and primary microglia were shaken at 250 rpm for 5 hours to dislodge 
microglia. The cells were then counted, centrifuged, resuspended in primary growth 
medium and seeded into a T-75 flask. At this point, culture times varied from overnight 
to one week. If the cells were cultured for more than 3 days, growth medium was 
changed. The primary microglia were treated with 2’(3’)-O-(4-benzoylbenzoyl)adenosine 
5’-triphosphate triethylammonium salt (Bz-ATP), which is a better stimulant of the P2X7 
receptors on microglia than ATP. The experimental procedure is the same as for BV-2 
mciroglia, although the amounts of reagents are smaller since the culture flasks used were 
smaller in size. Microglia were rinsed with 2 mL PBS, then 2 mL growth medium with 
100 µM BzATP was added. Cells were incubated 10 min at 37 °C in 5% CO2. 
Supernatant was collected and centrifuged at 2000xg for 20 min to remove apoptotic 
bodies. The supernatant, containing microvesicles, is collected, distributed into two 
labeled 1.5 mL microcentrifuge tubes, 1 mL each, and 3.8 µL 2-(6-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)amino)haxanoyl-1-hexadecanoyl-sn-glycero-3-phosphocholine (NBD C6-
HPC) was added to each tube (final [NBD C6-HPC] = 10 µM). Tubes were then 
centrifuged at 12,200xg for 40 mins to pellet the microvesicles (Crescitelli, et al., 2013). 
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Supernatants were removed and kept for further analysis. One of the pellets was 
reconstituted in 200-500 µL aCSF, then the entire volume was transferred to the second 
tube to reconstitute another pellet. This process was repeated for both tubes to resuspend 
and concentrate the microvesicles in one volume.  
2.10 Fluorescence measurements of microvesicles 
 2-(6-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl-1-hexadecanoyl-sn-
glycero-3-phosphocholine (NBD C6-HPC) (Life Technologies) is a fluorophore 
conjugate that inserts into phospholipid membranes. The presence of microvesicles in the 
aCSF solution described above (Methods 2.9) was determined using a Cary Eclipse 
fluorescence spectrophotometer. 70-100 µL of the microvesicle-NBD C6-HPC solution 
was placed in a quartz cuvette. Emission scans of 500-600 nm were obtained with an 
excitation wavelength of 485 nm. The resulting curves were integrated from 520-580 nm 
to produce relative fluorescence units (RFU).  
2.11 Confocal LSM imaging of microvesicles 
 Annexin V binding was used make the microvesicles visible via confocal 
microscopy. Annexin V binds to exposed phosphatidylserine (PS) on the external leaflet 
of cell membranes. PS is normally located only on the inner leaflet of the plasma 
membrane, but is externalized upon either apoptosis or the membrane blebbing that forms 
microvesicles. A conjugate of Annexin V and the Alexa Fluor 488 fluorophore 
(Invitrogen) will bind to exposed PS and so it was used to visualize microvesicles. The 
microvesicle generation from microglia (Section 2.9) was followed by resuspension of 
the pellets in 500 µL Annexin V binding buffer (10 mM HEPES, 140 mM NaCl, and 2.5 
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mM CaCl2, pH 7.4). Then 25 µL of -Annexin V conjugate was added, and after gentle 
mixing the solution sat at room temperature for 15 min. The solution was then 
centrifuged at 12,200xg for 40 min to pellet the microvesicles, the supernatant was 
removed, and the pellet was resuspended in 200 µL binding buffer. 50 µL of the 
microvesicle solution was placed on a microscope slide and a coverslip was carefully 
applied. Images were obtained with a Zeiss LSM 700 confocal microscope, with an 
excitation wavelength of 488 nm, using ZEN 2009 imaging and analysis software.  
2.12 Preparation of microvesicles for resin-embedded TEM 
The protocol used is based on the procedure described in Crescitelli, et al. (2013), 
and one of the authors, Dr. Agnes Kittel, was exceptionally helpful by offering 
suggestions when I requested details regarding the procedure in the published article. 
BV-2 supernatant samples were centrifuged at 12,200xg (or 17,000xg) for 40 mins. 
Supernatant was carefully removed and the pellet was rinsed once with PBS. 100 µL of 
fixing buffer (4% paraformaldehyde in 10 mM PO4 buffer, pH 7.4) was added to the 
pellet without disturbing it, and then incubation occurred at room temperature for one 
hour. After carefully removing fixing buffer, 100 µL 1% OsO4 in 10 mM PO4 buffer (10 
µL OsO4 in 990 µL buffer) was added to the pellet and allowed to incubate 30 min at 
room temperature. (SAFETY PRECAUTIONS for OsO4: gloves, coat, goggles, fume 
hood). OsO4 is a secondary fixing agent that incorporates reacts with lipids and provides 
contrast for TEM imaging. After incubation, OsO4 was removed and disposed of with 
proper safety precautions, and the pellet was washed once with 1 mL diH2O. An ethanol 
series was used to dehydrate the pellet (200 µL per tube for each step): 50% ethanol with 
2% uranyl acetate 30 min; 70% ethanol for 30 min; 90% ethanol for 30 min; and 100% 
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ethanol for 30 min. The 100% ethanol step was repeated twice. The pellet was then 
embedded in 0.2 mL Low Viscosity Embedding Media (Spurr’s Kit, Electron 
Microscopy Sciences) resin (supplied by David Osborn) and stored at RT overnight. Dr. 
Osborn then heated the resin to harden it, cut microtome slices 80 nm thick, and obtained 
TEM images.  
2.13 BCA Assay 
 A bicinchoninic acid (BCA) assay was utilized to measure protein concentrations 
in microvesicle solutions. In the BCA assay, Cu2+ is reduced to Cu1+ by the presence of 
four protein residues (cysteine, cystine, tyrosine, and tryptophan) and the peptide 
backbone. First, the copper is chelated and reduced by the proteins in a basic solution. 
Then BCA is used to react with the reduced copper, resulting in a purple color. By 
measuring absorbance at 562 nm and comparing the samples to a standard curve 
generated with bovine serum albumin, protein concentration within the MVs can be 
determined. A standard curve was constructed using bovine serum albumin (BSA) diluted 
in aCSF, typically in the concentration range of 0 µg/mL to 2000 µg/mL. Microvesicle 
samples (10 µl) were added to 100 µl of 50:1 mixture of BCA Reagent A to Reagent B 
(Thermo Fisher Scientific) and mixed thoroughly in individual wells of a 96-well plate. 
The plate was covered and incubated for 30 min at 37 °C followed by cooling for an 
additional 15 min. Absorbance was determined for each well at a wavelength of 562 nm 
using a SpectraMax 340 absorbance plate reader (Molecular Devices, Union City, CA). 
Mudar Ismail and Natan Zeller conducted the assays and I constructed the graphs. 
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CHAPTER 3: Ab INTERACTIONS WITH MICROGLIAL CELL SURFACES 
Ab42 is known to interact with microglial surface receptors, leading to uptake and 
activation (Section 1.3.1). Previous studies in our lab and had shown that protofibrils can 
activate a proinflammatory response in THP-1 macrophages and in microglia, while 
monomers and fibrils do not. Being aware of the difference in response to Ab 
conformers, we wanted to know if it was related to a difference in surface interaction. 
Therefore, my goal was the visualization of Ab42 on outer cell membrane surfaces using 
immunofluorescence. I examined the differences in surface binding among monomers, 
protofibrils and fibrils of Ab42. I also conducted studies investigating the effects of time, 
temperature, and Ab42 concentration on microglial surface interactions. Further, I 
investigated the correlation between Ab42 binding to microglia and the subsequent 
microglial activation. One distinguishing feature of my work was the use of SEC purified 
monomers and protofibrils, as well as fibrils isolated by centrifugation. This differed 
from most of the studies in the literature reporting the use of “soluble” Ab, which usually 
includes a mix of monomers and multiple aggregated forms. 
3.1 Binding of distinct Ab conformers 
 When BV-2 microglia were incubated with different forms of Ab42 – monomers, 
protofibrils and fibrils –immunofluorescence revealed that membrane binding was 
occurring only with protofibrils, as shown in Figure 3.1. BV-2 microglial cells were 
added at a concentration of 5 x 104 cells/mL in the wells of Mat-Tek dishes (Methods   
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Figure 3.1 Binding of distinct species of Ab. BV-2 microglia were incubated for 30 min 
at 4 °C with 15µM Ab42 monomers, protofibrils, or fibrils. Control cells were incubated 
with assay medium. Ab (green) was visualized via immunofluorescence with anti-Ab 
antibody Ab9 (primary) and anti-mouse IgG-NL493 conjugate (secondary). Nuclei were 
stained with DAPI (blue). C = control; M = monomer-treated cells; PF = protofibril-
treated cells; F = fibril-treated cells. Images were acquired at 40X magnification on a 
Zeiss LSM 700 confocal microscope. Scale bar is 16 µm and applies to all four images 
(Paranjape, Terrill, and Gouwens, et al., 2013).   
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2.4.3). The Mat-Tek dishes have wells with optical glass bottoms to facilitate sample 
visualization with an inverted microscope. BV-2 cells were incubated on ice with 15 µM 
Ab monomers, protofibrils or fibrils in assay medium, while the control cells were 
incubated in assay medium alone. After incubation, cells were fixed and underwent the 
confocal assay described in Methods 2.4.3, with Ab9 primary antibody and NL493-IgG 
secondary antibody. DAPI chemical staining was used to show cell nuclei. Images were 
obtained on the Zeiss LSM 700 located in the Microscope Imaging and Spectroscopy 
Technology (MIST) Laboratory in the UMSL Center for Nanoscience.  
The reason for holding the temperature at 4 °C was to slow the activity of the 
cells and prevent phagocytosis, allowing visualization of cell surface interactions. In 
Figure 3.1, monomer-treated cells (M) look like the control cells (C), with no visible 
green fluorescence that would indicate the presence of Ab inside or on the cells, while the 
cell nuclei (blue) are clearly visible. It is not likely that monomers were taken up and 
degraded by the microglia since the low temperature would have interfered with uptake 
and metabolic activities. The image of cells incubated with fibrils (F) shows green 
fluorescence scattered between the cells, rather than outlining cells, which indicates that 
fibrils adhered to the well but not to cell membranes. Only protofibrils (PF) could be seen 
on cell surfaces, and they were not readily visible within cells.  
One advantage of using the confocal microscope is the ability to acquire a “z-
stack” in which a number of images are made at successive depths within the field of 
view. These slices can then be rendered by Zeiss Efficient Navigation (ZEN) software to 
create cross-section images. The PF panel of Figure 3.1 shows this type of imaging. The 
thin rectangular section at the top of the image corresponds to a slice through the z-stack 
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made at the horizontal green line near the center of the image. Similarly, the rectangular 
region to the right corresponds to a slice through the z-stack at the location of the red 
vertical line on the image. In all three views of this field, Ab protofibrils are concentrated 
on the surface membranes of BV-2 cells. Similar results were seen in replicate 
experiments, leading to the conclusion that BV-2 cell membranes interact with 
protofibrils of Ab, but not monomers or fibrils.  
Binding of Ab to the cell surface membranes of monocytes was assessed 
previously by Bamberger, et al. (2003), and they identified a receptor complex consisting 
of SR-B receptor CD36, a6b1-integrin, and integrin associated protein CD47 which was 
responsible for the interaction. In their binding assays, they used Ab fibrils adhered to 
glass slides, applied monocytes to the slides, and counted the number of cells adhering to 
the pre-treated slides after a 5-minute incubation. This group was able to show cells 
binding to fibrils, but the quantity of Ab used was large enough that the fibrils were 
visible to the unaided eye on the slides. It’s possible that the amount of Ab enhanced the 
binding and accounts for the difference between our results and theirs. Additionally, fibril 
binding may be different for monocytes and microglia. 
We did not address the binding of oligomeric Ab to microglia, but this was 
investigated by Liu, et al. (2012). They were able to show images of oligomers bound to 
microglial surfaces and colocalized with toll-like receptor 2 (TLR2), but the binding was 
limited and punctate, while the binding of protofibrils shown here almost completely 
covers the cells. The difference could be due to the nature of protofibrils and oligomers 
since they are different types of Ab aggregates. 
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It is likely that the hydrophobic nature of protofibrils allows them to bind to the 
cell membrane indiscriminately even as they trigger receptor-mediated responses in 
microglia. Some microglial surface receptors are activated by protofibrils (Section 1.3.1), 
resulting in the production of proinflammatory cytokines, and we have confirmed the 
secretion of TNFa by BV-2 microglia as a result of protofibril, but not monomer or fibril, 
treatment (Paranjape, et al., 2012; Paranjape, Terrill, Gouwens, et al., 2013). Several 
microglial receptors are known to interact with Ab, and they can be categorized into three 
types: scavenger receptors, G protein-coupled receptors, and toll-like receptors (reviewed 
in Yu and Ye, 2014). When distinguishing the Ab species involved in the interactions, 
most researchers identify “soluble” or “fibrillar” Ab, without further description. 
However, after centrifugation to remove pre-formed fibrils, we carefully separate 
monomers from protofibrils using SEC. To my knowledge, there are no published images 
that differentiate between these three forms of Ab in binding to microglia. 
3.2 Time-dependence of Ab42 interaction with BV-2 cell surfaces 
 The investigation of membrane interactions between BV-2 microglia and different 
conformers of Ab42 revealed that BV-2 cells most readily attract protofibrils, so the next 
set of experiments was conducted using this Ab species. A time-dependent measure of 
plasma membrane interaction was done by first incubating microglia at 4 °C for 30 min 
to allow surface binding while preventing internalization, then varying the times of 
incubation at 37 °C. Representative results from these experiments are shown in Figure 
3.2. Immunofluorescence revealed the location of Ab mainly on the exterior surfaces of 
the BV-2 cells at all time points measured. To rule out the possibility that cell membranes  
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Figure 3.2 Time dependence of surface binding to BV-2 microglia. BV-2 microglia were 
plated in Mat-Tek dishes at a density of 5 x 104 cells/mL in cell assay medium. On the 
following day, cells were treated with 15 µM Ab42 protofibrils in cell assay medium. All 
plates were incubated on ice for 30 min, then incubated for 0 (30/0), 30 (30/30), 60 
(30/60), or 120 (30/120) min at 37 °C. Immunofluorescence assay was conducted using 
anti-Ab Ab9 primary antibody and anti-mouse IgG-NL493 secondary antibody. Confocal 
images were acquired at 40X magnification with a Zeiss LSM confocal microscope. 
  
30/0  30/30  
30/60  30/120 
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were not permeable to the antibodies used in the immunofluorescence assay, an assay 
was conducted in which Triton-X 100 was applied to fixed cells before the antibodies 
were added. Images acquired after the immunofluorescence assay were nearly identical to 
those obtained without the permeabilizing reagent, confirming that the lack of 
fluorescence was not due to the inability of antibodies to reach internalized Ab (data not 
shown). From the results in Figure 3.2, it was apparent that BV-2 cells were not 
internalizing Ab42 even with 2 h of incubation at 37 °C. These results contradict findings 
from other groups in which BV-2 cells took up various Ab42 species (Jiang, et al., 2008; 
Koenigsknecht and Landreth, 2004; Kopec and Carroll, 1998; Mandrekar, et al., 2009; 
Tahara, et al., 2006; Webster, et al., 2001). The Ab42 conformers used in those studies 
included monomers, oligomers and fibrils, but were not prepared by SEC. The peptides in 
the “soluble” Ab  solutions probably contained some oligomers and protofibrils, while 
the fibrillar solutions most likely contained oligomers and protofibrils as well.  
3.3 Effect of temperature on Ab42 binding to BV-2 cell surfaces 
Another possibility for the difference in my results and previous studies is that 
treatment for 30 min at 4 °C was negatively affecting the BV-2 microglia such that 
uptake was compromised. With that in mind, I also conducted experiments in which the 
first 30-minute incubation was conducted at room temperature. The results (not shown) 
are similar to the images in Figure 3.2, with Ab42 collecting on the outer cell surfaces of 
the microglia. From the results in Figure 3.2, I realized that BV-2 cells are not 
internalizing Ab42 even with 2 h of incubation at 37 °C. Therefore, while they are not 
proficient at internalization, BV-2 microglia are a good model for cell surface binding in   
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Figure 3.3 Temperature effect on surface binding to BV-2 microglia. Cells were plated in 
Mat-Tek dishes, 5 x 104 cells/mL. On the following day cells were incubated with 15µM 
Ab42 protofibrils (green) in assay medium for 30 min at the indicated temperatures. Cells 
were fixed, underwent an immunofluorescence protocol with Ab9 primary Ab and IgG-
NL493 secondary Ab, and were counterstained with DAPI (blue). Images were obtained 
at 40X magnification on a Zeiss LSM 700 confocal microscope. (37 °C image from 
Paranjape, Terril, and Gouwens, et al., 2013.) 
Control  4°C  
37°C  RT  
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our culture system. Using immunofluorescence, Ab42 could be visualized on BV-2 
microglial surfaces, binding at 4 °C, room temperature (RT), and 37 °C (Figure 3.2). In 
Mat-Tek dishes, BV-2 cells were incubated for 30 minutes with 15 µM Ab42 protofibrils, 
while control cells were untreated but incubated at room temperature in assay medium 
with aCSF for the same amount of time. After cell fixing, the immunofluorescence assay 
(Methods 2.6) was conducted and then followed by counterstaining with DAPI, and 
images were acquired on a Zeiss LSM 700 confocal microscope. Figure 3.3 shows that 
binding occurs on the outer surface of the cell membrane at each temperature measured, 
but protofibrils were not taken up by the BV-2 microglia within the 30 minutes of 
incubation. If Ab protofibrils were internalized, green fluorescence would be visible 
throughout the cells, rather than concentrated on the membrane boundaries. The z-stack 
views confirm that, for all three temperatures, protofibrils accumulate at BV-2 cell 
surfaces in our system. While the groups cited above (and shown in Table 3.1) 
demonstrated uptake at various time points, the species of Ab42 they used varied in size 
from monomers to fibrils, and none were SEC-purified protofibrils. 
3.4 Effect of Ab42 concentration on binding to BV-2 cell surfaces 
 We reported concentration-dependent production of TNFa by microglia in 2012 
(Paranjape, et al., 2012). Both primary and BV-2 microglia showed increased TNFa 
production upon incubation with increasing concentrations of Ab. While the Ab 
treatments reported in 2012 were carried out in F-12 medium (131 mM NaCl, 3 mM KCl, 
1 mM NaH2PO4, 14 mM NaHCO3, 0.003 mM MgCl2, 0.3 mM CaCl2, 10 mM glucose), 
the work reported in 2013 utilized artificial cerebrospinal fluid, (aCSF; 130 mM NaCl, 3   
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Table 3.1 Ab internalization in BV-2 microglia and other cell lines 
 
Reference Ab form Ab label [Ab], µM Cell type Incuba-
tion time 
Uptake (method) 
 
Kopec and 
Carroll, 
1998 
 
“aged” 
(probably 
fibrillar) 
 
unlabeled 
(fluorescent 
microspheres) 
or free Ab 
 
5 
 
BV-2 
 
1 h 
yes (flow 
cytometry) 
 
Webster, et 
al., 2001 
 
fibrils 
 
fluorescein 
 
10 
 
BV-2  
 
30 min 
 
yes (FACS, 
fluorescence 
microscopy) 
 
Koenig-
schnect 
and 
Landreth, 
2004 
 
fibrils 
(oligomers 
possibly 
present) 
 
Cy3 
 
10 
 
BV-2 
 
30 min 
 
yes (confocal 
microscopy) 
 
Tahara, et 
al., 2006 
 
polydisperse 
mixture 
 
none 
 
1 
 
BV-2 
 
24 h 
 
yes (western blot, 
ELISA, 
immunofluores-
cence) 
 
Halle, et 
al., 2008 
 
fibrils 
 
 
fibrils 
 
 
fibrils 
 
 
fibrils 
 
FITC 
 
 
HLF488 
 
FITC 
 
 
FITC 
 
10 
 
 
10 
 
 
10 
 
 
10 
 
immortalized 
mouse line 
 
immortalized 
mouse line 
 
immortalized 
mouse line 
 
immortalized 
mouse line 
 
4 h 
 
 
4 h 
 
 
1h 
 
 
4 h 
 
yes (confocal 
microscopy) 
 
yes (confocal 
microscopy) 
 
yes (confocal 
microscopy) 
 
yes (confocal 
microscopy) 
 
Jiang, et 
at., 2008 
 
monomers 
and small 
oligomers 
 
monomers 
and small 
oligomers 
 
monomers 
and small 
oligomers 
 
AF488 
 
 
 
AF488 
 
 
 
Cy3 
 
0.5 
 
 
 
up to 1 
 
 
 
0.5 
 
BV-2 
 
 
 
BV-2 
 
 
 
BV-2 
 
0-3 h 
 
 
 
3 h 
 
 
 
15 min 
 
yes (flow 
cytometry) 
 
 
yes (ELISA of 
lysates) 
 
 
yes (confocal 
microscopy) 
 
continued on next page  
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Table 3.1 Ab internalization in BV-2 microglia and other cell lines, continued 
 
Reference Ab form Ab label [Ab], µM  Cell type Incuba-
tion time 
Uptake (method) 
Mandre-
kar, et al., 
2009 
soluble or 
fibrillar 
 
 
monomers 
 
 
 
monomers 
 
 
monomers 
Cy3 
 
 
 
AF488 
 
 
 
Cy3 
 
 
Cy3 
0.5 
 
 
 
0.5 
 
 
 
0.5 
 
 
0.5 
BV-2 
 
 
 
BV-2 
 
 
 
BV-2 
 
 
BV-2 
3 h 
 
 
 
0-180 min 
 
 
 
3 h 
 
 
0-19 min 
yes (confocal 
microscopy and 
flow cytometry) 
 
yes (flow 
cytometry and 
lysate ELISA) 
 
yes (confocal 
microscopy) 
 
yes (confocal 
microscopy, live 
imaging) 
 
Reed-
Geaghan, et 
al., 2009 
 
fibrils (with 
oligomers) 
 
none 
 
2.5 
 
BV-2 
 
3-5 min 
 
yes (fluorescence 
microscopy) 
 
Fu, H, et al., 
2012 
 
fibril 
 
 
fibril 
 
 
fibril 
 
 
 
fibril 
 
AF488 
 
 
AF488 
 
 
AF488 
 
 
 
AF488 
 
0.5 
 
 
0.5 
 
 
0.05, 0.25, 
0.5, 1.0, and 
2.5 
 
0.5 
 
N9 cell line 
 
 
N9 cell line 
 
 
N9 
 
 
 
N9 
 
1 h 
 
 
0, 15, 30, 
60 min 
 
2 h or 5 d 
 
 
 
1 h 
 
yes (confocal 
microscopy) 
 
yes (flow 
cytometry) 
 
yes (flow 
cytometry) 
 
 
yes (confocal 
microscopy) 
 
Baik, et al., 
2016 
 
fibril 
 
FITC 
 
1 
 
BV-2 
 
24 h 
 
yes (confocal 
microscopy) 
 
Paranjape, 
Terrill, and 
Gouwens, et 
al., 2013* 
 
protofibrils 
 
none 
 
15 
 
BV-2 
 
30 min 
 
no (confocal 
microscopy) 
 
Gouwens, et 
al., 2016* 
 
protofibrils 
 
AF488 
 
5 
 
BV-2 
 
30 min 
 
no (confocal 
microscopy) 
 
Abbreviations: 
AF488: Alexa Fluor 488 
FITC: fluorescein isothiocyanate 
HLF488: HiLyte Fluor 488 
 
*results presented herein 
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mM KCl, 1 mM NaH2PO4, 15 mM NaHCO3). The same concentration-dependent effect 
on TNFa production was seen with BV-2 cells in aCSF, as shown in Figure 3.4 
(Paranjape, Terrill, and Gouwens, et al., 2013). BV-2 cells were treated with Ab42 at 
various concentrations. ELISAs were conducted on cell medium samples to measure 
TNFa, a proinflammatory cytokine produced by microglia when activated. Panel A of 
Figure 3.4 shows a concentration-dependent increase in TNFa production for BV-2 
microglia. The location of Ab42 on or in BV-2 microglia was assessed by 
immunofluorescence and confocal microscopy. Panels B and C of Figure 3.4 show very 
little fluorescence on the surfaces of BV-2 cells treated with 1 µM Ab42, while Panel D 
shows markedly more intense fluorescence on the BV-2 cell membranes. Taken together, 
these images reveal a concentration-dependent pattern of Ab binding to BV-2 cell 
membranes. These data are in agreement with the our research (Paranjape, et al., 2012; 
Terrill-Usery, et al., 2014) and the findings of other groups (Combs, et al., 2001; Meda, et 
al., 1995; Stewart, et al., 2010; Yan, et al., 1996) that microglia produce TNFa upon 
stimulation with Ab. 
3.5 Correlation of Ab42 binding and BV-2 activation 
 The surface interaction of Ab42 with BV-2 microglia leads to activation and the 
production of cytokines. Not all forms of Ab42 can elicit an inflammatory response as 
measured by cytokines, though. Our lab demonstrated this in 2012 (Paranjape, et al., 
2012) and 2013 (Paranjape, Terril, Gouwens, et al., 2013) via ELISA, but there were no 
images made at the time. In order to correlate binding with activation, I conducted an 
experiment that measured TNFa production as BV-2 cells encountered two different   
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Figure 3.4 Ab42 concentration dependence of cytokine secretion by BV-2 microglia. 
BV-2 cells were treated with 1 and 15 µM Aβ42 for 30 min at 37 °C. (A) TNFα 
ELISA; (B & C) Confocal micrographs of cells incubated with 1 µM Aβ42; (D) 
Confocal micrograph of cells incubated with 15 µM Aβ42. Green: Aβ42. Blue: nuclei 
(Paranjape, Terrill, Gouwens, et al. (2013) 
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Ab42 conformers, and obtained confocal LSM images of BV-2 interactions with the 
different forms of Ab42 in a parallel experiment. Experiments were carried out on the 
same day, with microglia seeded from one batch of cells and Ab from the same labeled 
preparation. The only difference was incubation time, because longer time periods were 
needed for the TNFa part of the experiments in order to generate measurable amounts of 
the cytokine. The data in Figure 3.5 shows the distinct effects that monomers and 
protofibrils have on BV-2 microglia. Panel A reveals that BV-2 microglia secrete more 
TNFa in the presence of protofibrils than monomers, especially at 6 h. The images in 
Panel B show that the difference in activation is correlated with distinct interaction 
differences, i.e., BV-2 cells are more prone to interact with protofibrils than monomers. 
The report by our lab in 2013 was the first to distinguish between monomers, protofibrils 
and fibrils in the activation of primary murine microglia. To my knowledge, no one has 
previously shown both images and ELISA data to distinguish between activation due to 
monomers and protofibrils in BV-2 microglia. 
 
 
 
  63 
 
 
Figure 3.5 Correlation of Ab42 binding and BV-2 cell activation. BV-2 microglia were 
treated with AF488-Ab to correlate conformer binding with activation. (A) At 2 and 6 h 
time points, TNFa production is greater for protofibril-treated cells than monomer-
treated cells. (B) Images show that BV-2 cells associate with protofibrils but not 
monomers. Green = AF488-Ab fluorescence; blue = nuclei (DAPI) fluorescence. 
 
  
Control Monomer Protofibril
A 
B 
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CHAPTER 4: SELECTIVE INTERNALIZATION OF Ab BY MICROGLIA 
 Having demonstrated differential binding of Ab42 species to microglia, and the 
resulting activation of the cells, I sought to determine the fate of Ab42 once it was 
internalized by microglia. The Alexa Fluor® 488-TFP (AF488-TFP) fluorophore was 
used to label Ab42 in solutions containing a mix of monomers and protofibrils. The 
mixture was labeled before SEC purification based on a report by Jungbauer and 
coworkers (2009) showing that labeling peptides after the formation of oligomers and 
fibrils, rather than before, resulted in AF488-Ab that was most similar to unlabeled Ab. 
After conjugation of the fluorophore to Ab, AF488-monomers and –protofibrils were 
separated by SEC. The labeling process and characterization of labeled Ab42 is described 
in the Methods chapter, Section 2.2. It proved advantageous to use fluorophore-labeled 
Ab because direct fluorescence provided higher quality images than immunodetection, 
required less time to prepare cells for imaging than immunofluorescence assays, and 
allowed live cell imaging. My objectives were to compare monomer and protofibril 
uptake, assess the time- and concentration-dependence of uptake, determine if uptake has 
a limit using mixtures of labeled and unlabeled Ab, and confirm colocalization of Ab 
with cellular lysosomes. 
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4.1 Comparison of unlabeled and fluorescently-labeled Ab42 monomer, protofibril, and 
fibril interactions with BV-2 and primary microglia  
 Once the AF488-Ab had been characterized (Methods 2.2), I set out to assess and 
compare the interactions of both BV-2 and primary murine microglia with the labeled 
peptide. I wanted to be sure the binding of AF488-Ab to BV-2 microglia was similar to 
cell surface binding observed with unlabeled Ab. Further, I wanted to be sure that the 
interactions of primary microglia with AF488-Ab were similar to unlabeled Ab. In both 
cases, I found that the fluorophore label was not affecting Ab-cell interactions. Unlabeled 
Ab42 was detected via immunofluorescence, and three comparisons are shown in Figure 
4.1. The top two panels compare primary microglia treated with 5 µM unlabeled (left) 
and labeled (right) monomers for 30 min, with no significant differences between the 
images. There is a negligible amount of green fluorescence shown in the images, which 
indicates that monomers have not been internalized by the primary microglia. Previous 
data shows that BV-2 microglia do not bind or internalize Ab42 monomers (Paranjape, 
Terrill, and Gouwens, et al., 2013), and these images confirm that finding for AF488-
Ab42 monomers. Primary microglia incubated with 5 µM protofibrils for 30 min are 
shown in the middle two panels, unlabeled on the left and labeled on the right. The green 
fluorescence in the images indicates the location of Ab42. Again, there is virtually no 
difference in how primary microglia interact with protofibrils either with or without a 
label. The bottom two panels show a comparison of BV-2 microglial surface interactions   
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Figure 4.1 The AF488 fluorophore does not affect microglial interactions with Ab. 
A & B: primary microglia with unlabeled and labeled monomers, respectively (10 µM, 
10 min, 37 °C); C & D: primary microglia with unlabeled and labeled protofibrils, 
respectively (5 µM, 10 min, 37 °C); E & F: BV-2 microglia with unlabeled and labeled 
protofibrils, respectively (5 µM, 30 min, RT). Green – Ab; blue – cell nuclei 
 
  
A B 
C D 
E F 
Unlabeled Ab AF488-Ab 
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with both unlabeled (left) and labeled (right) protofibrils upon incubation for 30 min with 
5 µM Ab. Most of the Ab42 (green fluorescence) is located on the surfaces of BV-2 cells. 
As with the previous comparisons, the two images are similar, indicating that the label 
does not affect BV-2 microglial interaction with AF488-Ab.  
 Additionally, the proinflammatory responses measured by TNFa production show 
that primary microglia are activated and produce TNFa when treated with AF488-Ab 
protofibrils, but not monomers. Figure 4.2, panel C, shows ELISA results for primary 
microglia treated with monomers and protofibrils of labeled Ab. Primary microglia were 
activated and produced high quantities of TNFa only when incubated with AF488-Ab 
protofibrils. These data agree with our previous results from BV-2 microglia treatments 
and primary cell experiments with unlabeled Ab (Paranjape, et al., 2012; Paranjape, 
Terrill, Gouwens, et al., 2013).  
4.2 Time dependent internalization of AF488-Ab by primary microglia 
 We had often conducted cell treatments for 30 min or more, yet macropinocytosis 
of Ab42 can occur in just a few minutes in microglia (Tables 1.1 and 1.2). To determine 
how quickly uptake can occur in our primary microglia, AF488-Ab treatments were 
performed as described in Methods 2.4.1. Representative of multiple fields from at least 
two experiments, Figure 4.2, Panel A, provides visualization of uptake at four time-points 
(green fluorescence is AF488-Ab42, blue is cell nuclei). Monomer internalization is 
shown in the top row, and protofibril uptake in the bottom row of Panel A. Compared to 
monomers, which show a low level of internalization at all four measured time points, 
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Figure 4.2 Internalization of AF488-Ab by primary microglia. Uptake is time dependent 
for protofibrils but not monomers. (A) Images of time-dependent uptake of monomers 
(top) and protofibrils (bottom). (B) Quantitation of image fluorescence intensity. (C) 
TNFa ELISA for the same experiments. 
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protofibril internalization is much more robust. Recalling that the stoichiometry of 
labeling was about four times higher for monomers than protofibrils, shown in Table 2.1, 
it is striking that the fluorescence is so much more intense for protofibrils than 
monomers. This is an indication of the speed and extent of Ab42 protofibril 
internalization by primary microglia. While the visual evidence is compelling, 
quantitation of the images provides more objective evidence of the difference between 
monomer and protofibril uptake. By measuring fluorescence intensity per cell in multiple 
fields from two different experiments, the graph shown in Figure 4.2, Panel B, was 
produced. The data clearly indicate that protofibrils are quickly internalized by primary 
microglia, and the uptake of AF488-Ab42 protofibrils increases with time. Also, 
monomers are taken up at much lower amounts than protofibrils, even at longer 
incubation times.  
Monomer uptake (Jiang, et al., 2008; Taneo, et al., 2015) and soluble Ab uptake 
(Chu, et al., 1998; Chung, 1999; Hjorth, et al., 2010; Jiang, et al., 2008; Liu, et al., 2010; 
Mandrekar, et al., 2009) have been demonstrated by other research groups, and all except 
Chu (1999) used labeled Ab. However important differences are present between their 
studies and ours. With regard to monomers, Jiang reported a mix of monomers and 
soluble Ab, and the Taneo experiments were carried out for 24 h, which is enough time 
for monomers to aggregate. In either case, the uptake was most likely of something larger 
than monomers. As for the groups reporting internalization of “soluble” Ab, the uptake 
was likely not of monomers since soluble species include oligomers and protofibrils. 
Another difference involves treatment time points. These experiments involved longer 
time points, hours to even days, allowing plenty of time for oligomers and protofibrils to 
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form and be taken up. Their data is better compared to our results with SEC-purified 
protofibrils in Figure 4.2. 
 As part of the same internalization experiments, microglial activation was 
measured at these time points by looking at cytokine production. The ELISA results 
shown in Figure 4.2, Panel C, reveal that the amount of TNFa produced correlated with 
AF488-Ab42 protofibril internalization by microglia. At 5 and 10 min of treatment, 
measurable TNFa is not present for AF488-Ab42 monomers or protofibrils, but 
protofibrils produced a greater amount of TNFa than monomers at 30 min and 6 h.  
 In another set of experiments, time-dependent uptake of protofibrils and 
monomers was quantitated with immuno-dot blot assays of primary microglia cell lysates 
using the procedure described in Methods 2.7. Extensive washing of the cells after 
incubation with AF488-Ab42, including an acid wash step to remove monomers or 
protofibrils bound to the cell surface, allowed quantitation of the intracellular AF488-
Ab42 at each time point. While there is virtually no uptake of AF488-Ab42 monomers at 
any of the time points (Figure 4.3 A & B), the quantity of AF488-Ab42 protofibrils taken 
up by primary microglia increases with time. These cell treatments were done in a 96-
well cell culture plate, and, before lysing the microglia, fluorescence measurements were 
made in a plate reader to determine the relative amounts AF488-Ab42 internalized at 
each time point (Figure 2.8 and Section 2.5 of Methods). The intracellular fluorescence is 
reported as a percentage of the fluorescence in the assay medium removed from the cells 
after incubation so that results from different experiments could be combined. The 
results, shown in Figure 4.3 Panel C, confirm the findings that protofibrils are more likely 
  
  71 
 
 
 
 
 
 
 
Figure 4.3 Primary microglia take up AF488-Ab protofibrils, but not AF488-Ab 
monomers, in a time-dependent manner. (A) Immuno-dot blot of cell lysates showing Ab 
internalization; representative of three different experiments. (B) Densitometry for 
immuno-dot blot in (A) using ImageJ (pixel intensity) for three experiments. (C) 
Quantitation of plate reader fluorescence, normalized to fluorescence in cell medium at 0 
h for three experiments. 
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than monomers to be taken up by primary microglia. Primary murine microglia show a 
clear preference for internalizing protofibrils over monomers. Comparison of SEC-
purified monomers and protofibrils is a novel contribution to the literature regarding 
microglial uptake of Ab. 
Interestingly, the protofibrils do not appear to be degraded even when microglia 
are incubated for 24 h with them. The resistance of Ab to breakdown confirms findings in 
the literature. In the late 1990s, Maxfield’s group showed that only a portion of what they 
characterized as “microaggregates” (probably oligomers and/or protofibrils) was 
degraded by primary murine microglia, most of the Ab remained in the cells (Chung, 
1999; Paresce, et al., 1997). Cole and colleagues (1999) reported a 50-60% decrease in 
fibrillar Ab in rat microglia after a 24-h treatment. Conducting pulse-chase experiments 
in which the treatment medium containing excess Ab was removed, several groups noted 
that Ab was retained in primary microglia (Jiang, et al., 2016; Majumdar, et al., 2008; 
Majumdar, et al., 2007; Shibuya, et al., 2014). Yang, et al., (2011) were able to show 
complete degradation of oligomeric Ab after a 30-minute treatment followed by a 30-
minute chase, but that is likely due to the fact that they were using oligomers, which have 
a different structure than protofibrils. There is a constant supply of Ab being produced in 
the brain, so, while a pulse-chase experiment has some value for assessing degradation 
rates, it does not accurately reflect physiological conditions. 
4.3 Effect of AF488-Ab concentration on primary microglial uptake 
 This goal for this set of experiments was to determine the effect of AF488-Ab42 
concentration on internalization by microglia, comparing monomers to protofibrils. 
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Primary microglia were incubated for 10 min (37 °C, 5% CO2) with varying 
concentrations of AF488-Ab monomers or protofibrils. As seen in the Figure 4.4 
confocal images (Panel A) AF488-Ab monomer uptake is extremely low at all four 
concentrations tested, and only slightly visible at 5 and 10 µM concentrations. On the 
other hand, AF488-Ab protofibrils are visible in the cells even at 0.5 µM, and 
fluorescence appears to increase in intensity as the concentration increases. The 
quantitation results in Panel B of Figure 4.4 confirm these observations. The integrated 
fluorescence intensity acquired in the AF488 channel for each image was divided by the 
number of nuclei in the DAPI channel for each image. Results from three different 
experiments were combined. At all four concentrations examined, protofibrils are 
internalized at a greater extent than monomers, and internalization of AF488-Ab 
protofibrils increases as concentration increases. Once again, it is important to note that 
monomers had a higher stoichiometry of labeling, yet the intracellular fluorescence 
intensity is markedly stronger for protofibrils. Concentration-dependence of Ab uptake 
has been demonstrated in primary murine microglia and in the BV-2 and N9 microglial 
cell lines (Fu, et al., 2012; Liu, et al., 2005; Mandrekar, et al., 2009; Yang, et al., 2011), 
but as Table 4.1 summarizes, none of these groups compared monomers and protofibrils 
purified by SEC as we did. The protofibril uptake findings reported here are novel to the 
scientific literature. 
4.4 Non-saturable Ab uptake in primary microglia 
 If there is a limit to the protofibril quantity that can be ingested by primary 
microglia, it might be possible to use a mixture of both labeled and unlabeled Ab42 to  
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Table 4.1 Primary microglia Ab uptake experiments 
Reference Ab conformation Ab label [Ab], µM  Cell 
type 
Incubation 
time 
Uptake (method) 
 
Ard, et al., 
1996 
 
“not fibrillar” 
 
35S-Met 
 
0.22, 1.1, 
4.4, or 25 
 
rat 
primary 
 
24 or 48 h 
 
yes 
(immunofluorescence; 
lysate immunoblot) 
 
 
Paresce, et 
al., 1996 
 
“microaggregates” 
<400 nm length 
 
Cy3 
 
 
 
Cy3 
 
 
 
unlabeled 
 
0.22 
 
 
 
up to 11 
 
 
 
4 
 
mouse 
primary  
 
 
mouse 
primary  
 
 
mouse 
primary  
 
10 min 
 
 
 
15 min 
 
 
 
30 min 
 
yes (fluorescence 
microscopy, not 
confocal) 
 
yes (fluorescence 
microscopy, not 
confocal) 
 
yes (fluorescence 
microscopy, not 
confocal 
 
Paresce et 
al., 1997 
 
“microaggregates” 
 
Cy3 
 
 
 
 
Cy3 
 
 
 
 
125I 
 
 
 
 
unlabeled 
 
1 
 
 
 
 
2 
 
 
 
 
0.2 
 
 
 
 
2 
 
mouse 
primary 
 
 
 
mouse 
primary 
 
 
 
mouse 
primary  
 
 
 
mouse 
primary 
 
15 min, 
followed by 
3 h to 6 d 
chase times 
 
1 h, 
followed by 
1 h or 2 d 
chase 
 
1 h, 
followed by 
up to 75 
min chase 
 
1 h, 
followed by 
6 and 24 h 
chase 
 
yes (confocal LSM) 
 
 
 
 
yes (confocal LSM) 
 
 
 
 
yes (cell associated 
radioactivity) 
 
 
 
yes 
(immunofluorescence) 
 
Chung, et 
al., 1999 
 
fibrils  
 
 
fibrils 
 
 
soluble 
 
 
soluble 
 
 
 
soluble 
 
125I 
 
 
Cy3 
 
 
125I 
 
 
Cy3 and 
unlabeled 
 
 
Cy3 
 
0.2 
 
 
0.2 
 
 
1 
 
 
1 + up to 
100 
unlabeled 
 
0.5 
 
mouse 
primary 
 
mouse 
primary 
 
mouse 
primary 
 
mouse 
primary 
 
 
mouse 
primary 
 
1 h, various 
chase times 
 
1 h, various 
chase times 
 
2 h, various 
chase times 
 
15 min 
 
 
 
1.5 h, 1 h 
chase 
 
 
yes (cell associated 
radioactivity) 
 
yes (confocal image 
quantitation) 
 
yes (cell associated 
radioactivity) 
 
yes (confocal image 
quantitation) 
 
 
yes (confocal 
microscopy) 
continued on next page  
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Table 4.1 Primary microglia Ab uptake experiments, continued 
Reference Ab conformation Ab label [Ab], µM  Cell 
type 
Incubation 
time 
Uptake (method) 
 
Cole, et al., 
1999 
 
fibrils 
 
 
 
none 
 
0.2 
 
rat 
primary 
 
24 h 
 
yes 
(immunofluorescence) 
 
Webster, et 
al., 2000 
 
“minimally 
aggregated” 
 
“minimally 
aggregated” 
 
14C  
 
 
fluorescein 
 
0-50 
 
 
5, 50 
 
rat 
primary 
 
rat 
primary 
 
2 h and 6 h 
 
 
2 h and 6 h 
 
yes (cell-associated 
radioactivity) 
 
yes 
(immunofluorescence) 
 
Liu Y, et al., 
2005 
 
fibrils/protofibrils 
 
 
 
fibrils/protofibrils 
 
 
 
fibrils/protofibrils 
 
biotin 
 
 
 
biotin 
 
 
 
biotin 
 
0.055, 
0.55, 5.5  
 
 
0.55 
 
 
 
0.55 
 
mouse 
primary 
 
 
mouse 
primary 
 
 
mouse 
primary 
 
1 h 
 
 
 
5, 30, 60, 
120 min 
 
 
5, 30 min; 
1, 2 h 
 
yes, (quantitation of 
confocal microscopy, 
AF488) 
 
yes, (quantitation of 
confocal microscopy, 
AF488) 
 
yes, (confocal 
microscopy, Cy3-
streptavidin) 
 
Townsend, 
et al., 2005 
 
fibrils 
 
 
fibrils 
 
 
fibrils  
 
FITC 
 
 
none 
 
 
Cy3 
 
0.3 
 
 
0.3 
 
 
0.05 
 
mouse 
primary 
 
mouse 
primary 
 
mouse 
primary 
 
15, 30, 60 
min 
 
1 h 
 
 
1 h 
 
yes (fluorometry of 
lysates) 
 
yes (western blot of 
lysates) 
 
yes (confocal 
microscopy) 
 
Floden and 
Combs, 
2006 
 
fibrils 
 
FITC 
 
0.5 
 
primary 
mouse, 
neonatal 
and aged 
 
6 h 
 
yes (fluorometry) 
 
Tahara, et 
al., 2006 
 
oligomers 
 
none 
 
0.25 
 
mouse 
primary 
 
24 h 
 
 
yes 
(immunofluorescence 
microscopy) 
 
Majumdar, 
et al., 2007 
 
fibrils 
 
Cy3 
 
1 
 
mouse 
primary 
 
60 min, 
then 72 h 
chase 
 
yes (fluorescence 
image quantitation) 
 
Mandrekar, 
et al., 2009 
 
soluble 
(monomers with 
some small 
oligomers) or 
fibrillar 
 
Cy3 
 
 
 
 
0.5 
 
mouse 
primary 
 
3 h 
 
 
yes (confocal 
microscopy and flow 
cytometry) 
continued on next page  
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Table 4.1 Primary microglia Ab uptake experiments, continued 
Reference Ab conformation Ab label [Ab], µM  Cell 
type 
Incubation 
time 
Uptake (method) 
Liu Z, et al., 
2010 
soluble HLF555 2 
 
primary 
murine 
2 h yes (confocal 
microscopy) 
Majumdar, 
et al., 2011 
fibril Cy3 0.25 primary 
murine 
1 h, chase 
times vary 
yes (confocal 
microscopy) 
Yang, et al., 
2011 
oligomer 
 
 
oligomer 
 
 
oligomer 
none 
 
 
none 
 
 
FAM 
1 
 
 
0.5, 1.0, 
2.5, 5.0 
 
1 
primary 
murine 
 
 
primary 
murine 
 
primary 
murine 
5 and 30 
min; 1 and 
4 h 
 
30 min 
 
 
15 min 
yes (confocal 
microscopy) 
 
 
yes (fluorescence 
intensity quantitation) 
 
yes (confocal 
microscopy) 
Fu, H, et al., 
2012 
fibril 
 
 
fibril 
 
 
fibril 
AF488 
 
 
AF488 
 
 
AF488 
0.5 
 
 
0.5 
 
 
0.5 
primary 
murine 
 
primary 
murine 
 
primary 
murine 
1 h 
 
 
0, 15, 30, 
60 min 
 
1 h 
yes (confocal 
microscopy) 
 
yes (flow cytometry) 
 
yes (confocal 
microscopy) 
Lee, CY, et 
al., 2012 
soluble 
 
 
soluble 
AF555 
 
 
AF555 
0.4 
 
 
0.2 
primary 
murine 
 
primary 
murine 
18 h 
 
 
7 min, 10 
min chase  
yes (flow cytometry) 
 
 
yes (confocal 
microscopy) 
Taneo, et 
al., 2015 
monomer 
 
 
oligomer 
 
 
fibril 
none 
 
 
none 
 
 
none 
10 
 
 
10 
 
 
10 
primary 
murine 
 
primary 
murine 
 
primary 
murine 
24 h 
 
 
24 h 
 
 
24 h 
yes (confocal 
microscopy) 
 
yes (confocal 
microscopy) 
 
yes (confocal 
microscopy) 
Baik, et al., 
2016 
fibril (PF) FITC 1 primary 
murine 
24 h yes (confocal 
microscopy) 
Gouwens, et 
al., 2016* 
monomers 
 
 
 
 
protofibrils 
 
 
 
 
AF488 
 
 
 
 
AF488 
0.5 – 10 
 
 
 
 
AF488 
primary 
murine 
 
 
 
primary 
murine 
0-24 h 
 
 
 
 
0-24 h 
no (confocal 
microscopy; 
immunodot-blot; plate 
reader 
 
yes (confocal 
microscopy; 
immunodot-blot; plate 
reader) 
Abbreviations: AF488: Alexa Fluor 488; AF555: Alexa Fluor 555; Cy3: Cyanine 3; FAM: 
carboxyfluoroscein; FITC: fluorescein isothiocyanate; HLF488: HiLyte Fluor 488 
 
*work presented herein  
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Figure 4.4 Concentration-dependent internalization of AF488-Ab by primary microglia. 
(A) Images of monomer-treated (top) and protofibril-treated (bottom) cells. 
Concentrations indicated above columns. Green – AF488-Ab, blue – nuclei. (B) 
Quantitation of fluorescence intensity for AF488-Ab. Fluorescence intensity for the fields 
imaged in panel A and two other experiments. ImageJ was used to measure integrated 
intensity, which was then divided by the number of nuclei in the field. 
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visualize such a limit. Uptake that is receptor-mediated or regulated by a transport 
mechanism could prevent the internalization of ever-greater amounts of Ab42. By 
maintaining a constant AF488-Ab42 concentration while increasing the amount of 
unlabeled Ab42, a decrease in fluorescence would indicate that cells were saturated with 
Ab and could not internalize any more. If the fluorescence intensity is not diminished by 
increasing the ratio of unlabeled Ab, then the uptake mechanism cannot be saturated (up 
to the total amount of labeled + unlabeled Ab in the experiment). To probe the limits of 
uptake by primary microglia, unlabeled and AF488-Ab42 were mixed in various ratios 
before application to and incubation of microglia. As seen in Figure 4.5, Panel A, the first 
set of experiments did not indicate a saturation of uptake even at 20 µM total Ab42. All 
three images show similar green fluorescence intensity, indicating AF488-Ab 
internalization was not saturable. Different AF488-Ab:unlabeled Ab ratios were used in 
another set of experiments, and the image fluorescence intensity quantitation is shown in 
Panel B of Figure 4.5. Again, there is no significant difference in measured fluorescence 
intensity, even when there is three times as much unlabeled Ab42 mixed with AF488-
Ab42. These results confirm the findings of Mandrekar et al. (2009) that Ab uptake is not 
receptor-mediated, and in addition show that there is no limit to internalization up to 20 
µM Ab42. These images show internalized Ab, only the fluorescence on the boundaries 
of the cells could be considered as surface-attached Ab. We have shown that the amount 
of internalized Ab increases at 6 and 24 h, an increase that would not be present if the 
protofibrils were rapidly cycling into and out of the cells. Additionally, it is not likely that 
the membranes of the cell could support a rapid turnover leading to equilibrium. Other  
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Figure 4.5 Competition/saturation images and quantitation. (A) Representative images of 
primary microglia treated with the indicated concentrations of labeled and unlabeled Ab. 
(B) Quantitation of fluorescence intensity in images of primary microglia treated with the 
indicated concentrations of labeled and unlabeled Ab. ImageJ was used to measure 
integrated intensity for each field, which was divided by the number of nuclei in the field. 
(n = 2 experiments) 
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groups have conducted pulse-chase experiments in which the Ab-containing medium was 
removed and the amount of internalized Ab was then measured at different time points. 
but their purpose was to measure degradation, not uptake saturation (Chung, 1999; Lee, 
et al., 2012; Majumdar, et al., 2011; Majumdar, et al., 2007; Paresce, et al., 1997). While 
these groups did show some degradation, it was limited. Even if degradation occurred in 
the experiments reported here, it would not be enough to affect the outcome because the 
rate of degradation would not be enough to offset uptake, and the rate would be the same 
for all of the ratios. Two early studies, involving “microaggregates” or fibrillar Ab 
seemed to indicate saturation of uptake, as both groups found that intracellular 
fluorescence increased with increasing concentration, but leveled off after 10-11 µM Ab 
(Kopec and Carroll, 1998; Paresce, et al., 1996). These two groups did not use ratios as 
we did. Other studies used the approach of keeping the amount of labeled Ab constant 
while mixing in increasing concentrations of unlabeled peptide, and those groups did 
report saturation of uptake (Chung, 1999; Mandrekar, et al., 2009).  
4.5 Colocalization analysis of AF488-Ab with lysosomes 
 The question of whether or not Ab is degraded by microglia is not settled. Two 
reports indicated that oligomers are degraded in microglia (Shibuya, et al., 2014; Yang, et 
al., 2011) but oligomers do not have the same b-sheet structure as protofibrils or fibrils, 
so it is perhaps not surprising that they are degraded. Several studies showed slow and/or 
limited breakdown of internalized fibrils (Chung, et al., 1999 ; Majumdar, et al., 2011; 
Majumdar, et al., 2008; Majumdar, et al., 2007; Paresce, et al., 1997). Monomers and 
soluble species were also shown to be slowly or incompletely degraded (Ard, et al., 1996; 
Griciuc, et al., 2013; Jiang, et al., 2008). In these studies, there was no SEC purification 
  81 
of protofibrils, so it is possible that both the fibril and soluble solutions used contained 
some protofibrillar Ab. Further, the degradation was incomplete when it occurred at all, 
so more investigation is warrented. In cells, the break down unwanted material occurs in 
the lysosomes, acidic “digestive” organelles. If Ab is being degraded, it would first have 
to be trafficked to lysosomes. Many studies have shown Ab colocalized with lysosomes, 
and they are summarized in Table 4.1. Various Ab conformers were used for cell 
treatments in those experiments, but no one had reported using SEC-purified protofibrils. 
In an effort to show colocalization of protofibrils with lysosomes in our primary 
microglial system, I had tried using LysoTracker® Red DND-99 (Invitrogen) for labeling 
lysosomes prior to cell treatment, but did not have good enough results to definitively 
conclude colocalization or lack thereof. Lysosomal associated membrane protein 
(LAMP1) is a transmembrane protein that is found on lysosomes in many tissues. To 
visualize colocalization of Ab42 and lysosomes, I used immunofluorescence to label the 
LAMP1 protein. The primary antibody was anti-LAMP1 (Novus Biological) and the 
secondary antibody was anti-mouse IgG-NL637 (R & D Systems). Primary microglia 
were treated with AF488-Ab protofibrils, fixed, immunostained, counterstained with 
DAPI, and then imaged on a Zeiss LSM 700. The images in Figure 4.6 represent several 
experiments. Yellow arrows in the images indicate areas of colocalization (yellow) of 
AF488-Ab (green) with lysosomes (red). White arrows in the images show either AF488-
Ab (green) that is intracellular but not in lysosomes, or empty lysosomes (red). While 
other groups have shown Ab-lysosome colocalization in BV-2 and primary microglia, 
and some concluded that Ab is degraded in lysosomes, my results indicated that 
trafficking to lysosomes is not necessarily the fate of AF488-Ab protofibrils. This is  
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Table 4.2 Lysosome colocalization experiments.  
Reference Ab form Ab label [Ab], µM  Cell type Incubation 
time 
Colocalization  
method 
 
Ard, et 
al., 1996 
 
“not 
fibrillar” 
 
35S-Met 
 
0.22, 1.1, 4.4, 
or 25 
 
rat primary 
 
24 or 48 h 
 
immunogold, EM 
 
Paresce, 
et al., 
1996 
 
“microag-
gregates” 
<400 nm 
length 
 
Cy3 
 
 
0.22 
 
mouse 
primary   
 
10 min 
 
FITC-a2M  
 
Paresce et 
al., 1997 
 
“microag-
gregates” 
 
Cy3 
 
2 
 
mouse 
primary 
 
1 h,  
1 h or 2 d 
chase 
 
FITC-dextran  
 
Chung, et 
al., 1999 
 
soluble 
 
Cy3 
 
0.5 
 
mouse 
primary 
 
1.5 h, 1 h 
chase 
 
FITC-a2M  
 
Webster, 
et al., 
2000 
 
“minimally 
aggregated” 
 
fluorescein 
 
5, 50 
 
rat primary 
 
2 h and 6 h 
 
cathepsin D  
 
Liu Y, et 
al., 2005 
 
fibrils/protof
ibrils 
 
biotin 
 
0.55 
 
mouse 
primary 
 
5, 30 min;  
1, 2 h 
 
Lamp2  
 
Bolmont, 
et al., 
2008 
 
plaques 
 
none 
 
endogenous 
 
APP 
transgenic 
mouse, in 
vivo 
  
Lamp1 
 
Halle, et 
al., 2008 
 
fibrils 
 
 
 
fibrils 
 
 
 
fibrils 
 
FITC 
 
 
 
HL488 
 
 
FITC 
 
10 
 
 
 
10 
 
 
 
10 
 
immortal-
ized mouse 
line 
 
immortal-
ized mouse 
line 
 
immortal-
ized mouse 
line 
 
4 h 
 
 
 
4 h 
 
 
 
1h, 4 h 
 
Lamp1 
 
 
 
LysoTracker Red 
 
 
 
1 h: cathepsin B 
4 h: Lamp1 (no 
colocalization) 
 
Jiang, et 
at., 2008 
 
monomers 
and small 
oligomers 
 
Cy3 
 
0.5 
 
BV-2 
 
15 min 
 
LysoTracker Green 
 
Mandre-
kar, et al., 
2009 
 
monomers 
 
 
monomers 
 
Cy3 
 
 
Cy3 
 
0.5 
 
 
0.5 
 
BV-2 
 
 
BV-2 
 
3 h 
 
 
0-19 min 
 
Lamp1, Lamp2, Rab5 
 
 
LysoTracker Green 
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Table 4.2 Lysosome colocalization experiments, continued. 
Reference Ab form Ab label [Ab], µM  Cell type Incubation 
time 
Colocalization  
method 
 
Hjorth, et 
al., 2010 
 
soluble 
 
HL488 
 
0.25 
 
human 
CHME3 
line 
 
4 h 
 
Lamp2 
 
Liu Z, et 
al., 2010 
 
protofibril 
 
HL555 
 
0.4 
 
in vivo, 
mouse 
 
up to 4 d 
 
Lamp1 
 
Majum-
dar, et al., 
2011 
 
fibril 
 
Cy3 
 
0.25 
 
primary 
murine 
 
1 h, chase 
times vary 
 
Lamp1 
 
Yang, et 
al., 2011 
 
oligomer 
 
FAM 
 
1 
 
primary 
murine 
 
15 min 
 
DQ-BSA lysosome 
label 
 
Fu, H, et 
al., 2012 
 
fibril 
 
 
fibril 
 
fibril 
 
AF488 
 
 
AF488 
 
AF488 
 
66 (0.6 µg 
total) 
 
0.5 
 
0.5 
 
mouse in 
vivo 
 
N9 
 
primary 
murine 
 
2 h or 5 d 
 
 
1 h 
 
1 h 
 
Lamp1 
 
 
LysoTracker 
 
LysoTracker 
 
Lee, CY, et 
al., 2012 
 
soluble 
 
AF555 
 
0.2 
 
primary 
murine 
 
7 min, 10 
min chase 
 
fluorescent 
microspheres 
 
Taneo, et 
al., 2015 
 
monomer 
 
 
oligomer 
 
 
fibril 
 
none 
 
 
none 
 
 
none 
 
10 
 
 
10 
 
 
10 
 
primary 
murine 
 
primary 
murine 
 
primary 
murine 
 
24 h 
 
 
24 h 
 
 
24 h 
 
Lamp1 (not 
colocalized) 
 
Lamp 1 (not 
colocalized) 
 
Lamp1 (not 
colocalized) 
 
Baik, et al., 
2016 
 
fibril (PF) 
 
fibril (PF) 
 
 
 
FITC 
 
FITC 
 
1 
 
1 
 
BV-2 
 
primary 
murine 
 
24 h 
 
24 h 
 
LysoTracker 
 
LysoTracker 
 
 
Gouwens, 
et al., 2016 
 
protofibril 
 
AF488 
 
5 
 
primary 
murine 
 
30 min 
 
Lamp1 (partial 
colocalization) 
Abbreviations: AF488: Alexa Fluor 488; AF555: Alexa Fluor 555; Cy3: Cyanine 3; FAM: 
carboxyfluoroscein; FITC: fluorescein isothiocyanate; HLF488: HiLyte Fluor 488; HL555: 
HiLyte Fluor 555; 35S-Met: 35S-methionine radioisotope 
 
*work presented herein 
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evident in the increase of Ab protofibril load over a 24-h incubation (Figure 4.3) and in 
the confocal images of Figure 4.6 which show a significant amount of AF488-Ab 
distributed throughout the cytosol. The stability of intracellular SEC-purified protofibrils 
in microglia is a novel finding that was reported in Brain Research in 2016 (Gouwens, et 
al., 2016). 
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Figure 4.6 Lysosome colocalization. Three fields (top, middle and bottom rows) of 
primary cells treated with AF488-Ab show that much of the AF488-Ab remains outside 
of microglial cells. Yellow arrows indicate lysosome (red, Lamp1) and AF488-Ab 
(green) colocalization. White arrows show lysosomes that have no AF488-Ab within 
them. Nuclei are stained with DAPI (blue). 
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CHAPTER 5: MICROVESICLES 
 Having demonstrated that microglia internalize Ab protofibrils without 
bnecessarily degrading them, we began to wonder if the protofibrils are released from 
microglial cells. If there is a release of Ab, that could partly explain why plaques form in 
the AD brain. Structures called microvesicles (Section 1.4) are one way microglia could 
disperse Ab. Microvesicles (described in Section 1.4) are released by glial cells when 
P2X7 receptors are stimulated by ATP (Bianco, et al., 2005). In their work, Bianco and 
colleagues used the N9 murine microglial cell line as well as primary mixed cultures 
(containing astrocytes and microglia) from embryonic rat pups to demonstrate the release 
of microvesicles from microglial cells. Rat primary microglia (Joshi, et al., 2014), and 
human THP-1 monocytes and HEK cells (MacKenzie, et al., 2001) have also been used 
in experiments to produce microvesicles. Further, P2X7 receptors of microglia have been 
shown to mediate the inflammatory responses in rat hippocampus (McLarnon, et al., 
2006). My goals were to generate and characterize microvesicles from both BV-2 and 
primary murine microglia. 
5.1 Microvesicles from BV-2 microglia 
 Due to their small size, capturing a substantial amount of microvesicles requires 
treatment of many cells in an experiment. BV-2 microglia are relatively easy to culture in 
the amounts needed for microvesicle generation, so I started my experiments with them. 
Using T-150 flasks (Corning), which have a 150 cm2 growing surface, the BV-2 cells 
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were cultured to confluence. The experiments required two such flasks, a control flask 
that was incubated with 4 mL artificial cerebrospinal fluid (aCSF) and a second flask that 
was incubated with 1 mM ATP in 4 mL aCSF to stimulate the production of 
microvesicles (Methods 2.9). To confirm that microvesicles were produced, we employed 
a variety of techniques: fluorescently labeled Annexin V, BCA protein measurements, 
dynamic light scattering (DLS) measurements, transmission electron microscopy (TEM), 
and NBD C6-HPC fluorescence. 
5.1.1. A488-Annexin V visualization of BV-2 microvesicles 
 Annexin V is an anticoagulant protein that also has a high affinity for 
phosphatidylserine (PS). Normally PS is found on inner leaflets of the cell membrane,  
but, in apoptotic cells and microvesicles, PS is externalized (Hugel, et al., 2005). We used 
Annexin V conjugated to Alexa Fluor® 488 (AF488-AV) to visualize microvesicles 
generated in the experiments (Figure 5.1). After the cells were treated, the medium was 
subjected to centrifugation at 2000g for 20 minutes to remove apoptotic cells and cell 
debris from the medium. Soluble microvesicles are in the supernatant, to which AF488-
AV was added. After incubation at room temperature, the solution was then centrifuged 
at 12,200g for 40 minutes to pellet the microvesicles. The pellet was washed and 
resuspended, and microvesicles were mounted on slides and imaged using a Zeiss LSM 
700. As seen in Figure 5.1 A & B, the microvesicles are produced by both control (A) 
and ATP-treated (B) cells and are in the expected 100 – 1000 nm size range. 
Microvesicle production from the control cells (treated with aCSF only) is not necessarily 
surprising since microvesicles are routinely found in blood and spinal fluid (Budnik, et 
al., 2016), indicating constitutive generation by cells in the body. Panel C of Figure 5.1 is 
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a zoomed in view of an area near the center of Panel B which includes a 5 µm scale bar 
that confirms the size of the microvesicles. The images here are consistent with 
MacKenzie, et al. (2001), who showed a series of HEK cell images taken at 5 s intervals 
in which microvesicles are visualized with FITC-conjugated Annexin V bound to 
externalized PS. They imaged whole cells, and a halo of microvesicles is visible in the 
same size range as our microvesicles. Wilson, et al. (2004) demonstrated external PS 
(calling it “PS flip”) in human umbilical vein epithelial cells and murine macrophages. 
Their images were not of microvesicles, rather, they showed FITC-Annexin V binding to 
the surfaces of macrophages after treatment with ATP, demonstrating PS externalization. 
This is the same PS externalization that occurs with microvesicle release. Bianco, et al. 
(2005) also show FITC-Annexin V in close association with ATP-stimulated N9 
microglia, with a few blebs on the cell surface and structures that have the size and 
morphology of microvesicles. The researchers showed images of microvesicles in a 
subsequent publication, appearing as dots of fluorescence (Bianco, et al., 2009). One of 
the methods of microvesicle visualization used by Verderio, et al. (2012) was FITC-
Annexin V. Their image, similar to Bianco’s images, does not show the circular 
fluorescence seen in Figure 5C, which is indicative of hollow spheres. The images in 
Figure 5 indicate that our protocol for generating microvesicles from ATP-treated BV-2 
microglia and separating them from apoptotic bodies via centrifugation is successful. 
5.1.2. Bicinchoninic acid protein assay of BV-2 microvesicles 
 IL-1b has been found in microvesicles generated from human THP-1 monocytes 
(MacKenzie, et al., 2001) and dendritic cells (Pizzirani, et al., 2007), as well as murine 
microglia (Bianco, et al., 2005) treated with ATP. Therefore, we expected to find protein   
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Figure 5.1 AF488-Annexin V visualization of microvesicles from BV-2 cells. 
Microvesicles were generated from BV-2 microglia with or without ATP treatment. After 
generation from BV-2 microglia, microvesicles were incubated with AF488-Annexin V 
and imaged via confocal microscopy. (A) Control: microvesicles generated from 
microglia incubated in aCSF without ATP; 40X magnification. (B) Microvesicles 
generated from BV-2 microglia treated with 1 mM ATP. 40X magnification; vertical red 
scale bar = 20 µm; horizontal red scale bar = 5 µm. C. Zoomed in view of area near 
horizontal red scale bar in (B) 
A 
B 
C 
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in the BV-2 microvesicles. Bicinchoninic acid (BCA) protein assays were employed to 
provide measurements of overall microvesicle protein content. By measuring absorbance 
at 562 nm and comparing the samples to a standard curve generated with bovine serum 
albumin, protein concentration within the microvesicles can be determined. While both 
control and ATP-treated cells produced microvesicles, the microvesicles from treated 
cells had much more total protein (Figure 5.2), with virtually no protein in the 
microvesicles from control cells. The combined data from four preps showed a protein 
concentration of ~150 µg/mL protein in ATP-treated cells compared to virtually none in 
the control cells. It is likely that the contents of our microvesicles derived from ATP-
stimulated BV-2 microglia contain IL-1b, as was found by the MacKenzie, Pizzirani, and 
Bianco studies mentioned above. Regarding the control cells, constitutive microvesicle 
production is not unusual, and the lack of protein is likely a consequence of there being 
no ATP in the aCSF to activate IL-1b production and release.  
5.1.3. Dynamic light scattering characterization of BV-2 microvesicles 
 Particles in solution will move randomly as they collide with molecules of the 
solution, and smaller particles will move faster than relatively larger ones. Light passing 
into a solution containing microvesicles, for instance, will be scattered upon encountering 
a sphere crossing its path. Scattered light then encounters other particles, causing wave 
interference that is either constructive or destructive. As the particles diffuse through the 
solution, the scattering intensity changes, as does the correlation between the intensities 
and interferences. The intensity measurements are fitted to an autocorrelation curve, and 
from the exponential decay a diffusion coefficient can be calculated, which is then used 
to calculate hydrodynamic radii of microvesicles. We used these principles of dynamic 
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Figure 5.2 BCA assays. There is greater protein production in microvesicles generated 
from ATP-treated cells than control cells in aCSF. Average of four microvesicle 
preparations from BV-2 microglia. (BCA assays conducted by Mudar Ismail and Nathan 
Zeller; figure from Dr. Michael Nichols) 
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light scattering (DLS) to characterize microvesicle size (Methods 2.2.5). Histograms of 
percent intensity vs. hydrodynamic radius (RH) were generated by Dynamics software 
(Wyatt Technologies) data regularization, and intensity-weighted mean RH values were 
derived from regularized histograms. What we found, shown in the representative 
histograms in Figure 5.3, is that the microvesicles we isolated from BV-2 microglia are 
approximately 100-1000 nm in size, with an average RH = 129 nm for the ATP-treated 
BV-2 microvesicles in 5.3A, and an average RH = 207 nm for the microvesicles in 5.3B, 
which were also from ATP-treated BV-2 cells. Microvesicles generated from control 
cells in the same experiments had average RH = 136 and 208 nm, respectively. The 
defined microvesicle size range is 100-1000 nm, described by Budnik, et al. (2016), and 
these representative DLS data for all of the microvesicle preps show that our 
microvesicles were within that range  
5.1.4. Transmission electron microscopy of resin-embedded BV-2 microvesicles 
 Microvesicles from BV-2 cells were embedded in resin (Methods 2.11) for 
imaging via TEM. Dr. Agnes Kittel’s gracious help was vital to this endeavor. After 
reading a paper that featured TEM images of microvesicles (Crescitelli, et al., 2013), I 
emailed the corresponding authors and they identified Dr. Kittel as the TEM technician 
responsible for the images. Our correspondence led to the method used for obtaining the 
images of BV-2 microvesicles in Figure 5.4. The intricate process involved pelleting the 
microvesicles, fixing with formaldehyde, treatment with osmium tetroxide, multi-step 
alcohol dehydration using uranyl acetate stain in the first step, and resin polymerization. 
David Osborn acquired the images shown in Figure 5.4 after slicing the resin-embedded 
sample with a microtome. The top panel shows BV-2 microvesicles from control   
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5.3 Dynamic light scattering analysis of microvesicles. Microvesicles were generated 
from BV-2 microglia. Results from two different experiments are shown. (Figure created 
by Dr. M.R. Nichols.) 
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Figure 5.4 TEM of resin-embedded BV-2 microvesicles 
Top: control BV-2 MVs (no ATP). Bottom: ATP-treated BV-2MVs. Both sets of 
microvesicles are within the size range expected. (Resin embedding done by myself and 
Mudar Ismail; image by Dr. David Osborn.)  
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microglia, and the bottom panel shows BV-2 microvesicles from the ATP-treated 
microglia. The microvesicles are similar in size and appearance, despite the presence or 
absence of ATP during the experiment. Bianco (2009) and Verderio (2012) presented 
TEM of vesicles isolated by differential centrifugation, which they refer to as P2 (1200g), 
P3 (10,000g), and P4 (110,000g). The microvesicles from our experiments (Figure 5.4) 
correspond to their P3 pellet, and look much like the structures in their images. That is 
expected, considering the similarities in our isolation protocols; their 1200g and 10,000g 
centrifugations correspond to our 2000g and 12,200g centrifugations. The lower speed 
should pellet whole cells, debris, and apoptotic bodies, and the higher speed produces a 
pellet of microvesicles. In the Crescitelli, et al. (2013) study, three cell types were used: 
human mast cells, human erythroleukemia cells, and BV-2 murine microglia. They were 
able to visualize microvesicles from all three, and our BV-2 microvesicles resemble them 
in size and appearance. These images provide compelling evidence for our ability to 
generate microvesicles from BV-2 microglia. 
5.1.5 Tracking microvesicles with NBD C6-HPC fluorescence 
 The miniscule pellets presented a challenge when isolating microvesicles. To 
better track microvesicles, and reassure ourselves that they were indeed present, we took 
advantage of the NBD fluorophore conjugated to phosphatidylcholine (PC). The NBD 
C6-HPC (Setareh Biotech; Figure 5.5) molecule inserts into lipid bilayers, and its 
emission at 536 nm (excitation: 436 nm) can be used to identify membranes. The use of 
NBD C6-HPC to visualize microvesicles from healthy rat CSF and to quantify 
microvesicles from rat microglial cell culture was reported by Verderio, et al. (2012). 
CSF microvesicles isolated from healthy rats were visualized by adding NBD C6-HPC to 
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pellet fractions, placing drops onto a slide, and imaging the microvesicles with a 
fluorescence microscope. In their work, microglia were pretreated with NBD C6-HPC 
before the experiment to label cell membranes, then, after collecting the microvesicles, 
the researchers quantified NBD C6-HPC fluorescence intensity to make a comparison of 
microvesicle amounts produced by known stimulants of microglial activation and 
microvesicle production, such as ATP or LPS. Bianco, et al. (2009) also used NBD C6-
HPC to label cell membrane lipids and visualize both real-time microvesicle release from 
BzATP-treated human glioma cells and microvesicles isolated from cell the culture 
medium of BzATP-treated astrocytes.  
In our experiments, supernatants from microglia treated with ATP or BzATP were 
processed as described in Methods (2.9 and 2.10). NBD C6-HPC is added to the 
supernatant collected from the 2000g spin of the cell treatment medium, which pellets 
cell debris and apoptotic bodies. The supernatant with fluorophore is then incubated at 
room temperature for 10-15 min, after which the microvesicles are pelleted via 
centrifugation at 12,200-15,000g and washed with aCSF two to five times to remove 
excess fluorophore. A fluorimeter is used to measure fluorescence of the washes and 
resuspended pellets. Fluorescence emission is recorded from 500-600 nm, and integrated 
from 505-550 nm to produce the values that are graphed. Since most of the 
unincorporated fluorophore is removed during the washes, greater fluorescence intensity 
in the resuspended pellet compared to the last wash indicates the presence of 
microvesicles. Figure 5.5 shows representative data from an experiment in which BV-2 
and primary microglia were treated with ATP to stimulate microvesicle production. The 
bottom panel shows a comparison among two washes and the resuspended microvesicle  
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Figure 5.5 NBD C6-HPC fluorescence indicates the presence of microvesicles. 
Top: NBD PC conjugate. Bottom: representative fluorescence intensity measurements for 
microvesicles generated from BV-2 and primary microglia. Greater fluorescence intensity 
in the resuspended pellet than in the final wash confirms the presence of microvesicles. 
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pellet from ATP-treated primary microglia, and from treated and control BV-2 cells. For 
the ATP-treated BV-2 cells, the first wash has a fluorescence intensity of 11144, the 
second wash is 1465 and the pellet is 3658, 2.5-fold greater. This indicates that the NBD 
C6-HPC is embedded in the membranes of the microvesicles in the pellet. The washes 
from the control (aCSF-treated) BV-2 microvesicles had intensities of 5984, 899, and the 
pellet intensity was 1126. In this case, the pellet has only 25% greater intensity, but that 
is still much lower than the first wash, and it seems there fewer microvesicles in the 
control pellet than in the pellet from the ATP-treated BV-2 microglia. This representative 
result is typical of the microvesicle preparations we have done so far. 
5.2 Characterization of microvesicles from primary microglia 
 Generating microvesicles from primary microglia is challenging because it is 
difficult to culture primary microglia in the amounts needed to produce enough 
microvesicles to assay. Our primary microglia are in co-culture with astrocytes, so I first 
tried using a co-culture of microglia and astrocytes to generate MVs. The data were  
promising in that, after using NBD C6-HPC, I was able to detect greater fluorescence 
intensity in the microvesicles than in the final wash. However, both the control flask and 
the treated flask were not able to be used again after that experiment. New co-cultures 
require isolation from mouse pups, so their availability is limited. It is necessary, then, to 
use cultures of only primary microglia that are removed from the astrocyte + microglia 
co-culture. To isolate primary microglia for experiments, co-culture flasks are shaken for 
5 h at 250 rpm. From two T150 (Corning) flasks containing primary murine astrocytes 
and microglia, the yield of primary microglia has ranged from 5e4 to 8e5 cells/mL, which 
is not even enough to cover one T75 flask to confluence. An additional consideration was 
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the viability of the primary microglia seeded in a flask. We had previously plated primary 
microglia in 96-well plates for experiments, but I had no experience with primary 
microglia monocultures or experimenting on them in a culture flask.  
 First, I seeded four 25 cm2 flasks with 5x 104 cells/mL in 5 mL and cultured them 
for a week, changing the medium twice. The data showed promise, but fluorescence 
intensity from the microvesicles was only slightly more intense than 4th wash. However, 
from this I confirmed that the primary microglia could be cultured in a flask for at least 
one week. Next, 2 T-75 flasks were seeded with 1.6 x 105 cells/mL in 10 mL. After 5 
days of culture, with one medium change, these cells were used for a microvesicle 
generation experiment. Only 2 washes were done, as seen in Figure 5.5. After this, fewer 
co-culture flasks were available, allowing the seeding of just one T-75 flask at a time. 
With only one T-75 flask of primary microglia, I did not set up a control (untreated) flask 
when generating microvesicles from primary microglia. 
The data from an early experiment with primary cells is shown in Figure 5.5. For 
microvesicles generated from primary cells, the first wash had an integrated fluorescence 
intensity of 8269, the second wash was 842, and the pellet integrated intensity was 1564 
– nearly double that of the last wash. Later experiments were done with BzATP, which 
has been shown to be more effective at stimulating the P2X7 receptor. Results from those 
microvesicle experiments are similar, with about 2-fold greater integrated intensity for 
the resuspended pellet than the last wash, indicating the presence of microvesicles.  
 Following consistent generation of microvesicles from primary microglia, further 
investigation would involve experiments in which we treat primary microglia with Ab so 
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they internalize it, use BzATP to stimulate microvesicle production, and probe the 
microvesicles for Ab using immuno-dot blots and/or ELISAs. 
5.3 Overall conclusion 
We have shown that surface interaction of Ab with BV-2 microglia produces a 
proinflammatory response in the presence protofibrils, but not monomers or fibrils of Ab. 
The proinflammatory response, as measured by TNFa secretion, correlated with the time 
of exposure to Ab in BV-2 microglia. Primary microglia are much more likely to 
internalize SEC-purified protofibrils than monomers, as demonstrated by both time- and 
concentration-dependent treatments. SEC separation of Ab monomers and protofibrils is 
a strategy that we employ which sets apart our work from the literature on microglial 
uptake of Ab and explains differences between our findings and those of other groups. 
For instance, we reported that much of the Ab taken up by primary microglia is not 
degraded in the lysosomes. We were also able to show that we can generate 
microvesicles from BV-2 and primary microglia. Further investigation into whether these 
microvesicles can carry internalized Ab back out of microglia is warranted. 
The five novel findings from this research include (1) the labeling of a solution of 
monomers and protofibrils which are then separated by SEC; (2) protofibrils are 
internalized by primary microglia in greater quantities than monomers in both time-and 
concentration-dependent experiments; (3) quantitation methods utilizing a plate-reader to 
measure uptake of labeled Ab in cells that were treated in a 96-well culture plate; (4) Ab 
internalization could not be saturated, even when the concentration of unlabeled Ab was 
three-fold greater than labeled Ab; and, (4) contradictory to many reports in the literature, 
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a significant amount of internalized Ab was found in the cytoplasm, outside of 
lysosomes, and remained stable as protofibrils.    
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